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Coevolution between Mycobacterium tuberculosis (Mtb), the causative 
agent of tuberculosis, and the human host has been documented for thousands of 
years. Interestingly, while T cell immunity is crucial for host protection and survival, 
T cell antigens are the most conserved region of the Mtb genome. Hypothetically, 
Mtb adapts under immune pressure to exploit T cell responses for its benefit from 
inflammation and tissue destruction for ultimately transmission. 
EsxH, a gene encoding immunodominant TB10.4 protein, however, 
contains polymorphic regions corresponding to T cell epitopes. Here, I present two 
complementary analyses to examine how Mtb modulates TB10.4 for immune 
evasion. First, I use a naturally occurring esxH polymorphic clinical Mtb isolate, 
667, to investigate how A10T amino acid exchange in TB10.4 affect T cell 
immunity. To verify and identify the cause of the immunological differences, I 
construct isogenic strains expressing EsxHA10T or EsxHWT. In combination with our 
recent finding that TB10.44-11-specific CD8 T cells do not recognize Mtb-infected 
macrophages, we hypothesize that TB10.4 is a decoy antigen as it distracts host 
immunity from inducing other potentially protective responses. I examine whether 
an elimination of TB10.44-11-specific CD8 T cell response leads to a better host 
protective immunity. The studies of in vivo infection and in vitro recognition in this 
dissertation aim to provide a better understanding of the counteraction between 
immune evasion and protective immunity.  
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CHAPTER I: INTRODUCTION 
Tuberculosis and Pathogenesis 
A. Significance: Global Disease Burden 
Tuberculosis (TB) is a contagious disease caused by airborne 
Mycobacterium tuberculosis (Mtb) that transmits via cough. In spite of a 42% 
decrease in mortality rate between 2000 and 2018, TB still caused 1.5 million 
deaths in 2018—surpassing human immunodeficiency virus (HIV)—and ranked as 
the leading cause of death by an infectious agent and one of the top 10 causes of 
death worldwide (1). Mtb was estimated to infect over 10 million people in 2018 
alone, bringing the current total infection number to 1.7 billion people (1). A small 
proportion (5–10%) of Mtb-infected individuals will develop active TB disease 
during their lifetime and are able to transmit the mycobacteria to an average of 10 
(and up to 200) additional people per year. The probability of progression to active 
TB, however, increases among people coinfected with HIV, as HIV suppresses the 
immune system and hinders control of Mtb. Other risk factors include diabetes, 
malnutrition, smoking and alcohol consumption (2).  
Given this immense disease burden, prophylactic and post-exposure 
treatments are the logical steps toward eradicating TB. Once diagnosed, the 
current recommended post-exposure treatment for drug-susceptible TB is a 6-
month regimen of four first-line drugs: isoniazid, rifampicin, ethambutol and 
pyrazinamide; this serves to clear the infection and prevent development of 
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antibiotic resistance (3-5). Although antibiotic treatments cure approximately 85% 
of TB patients, an estimated 484,000 people developed drug-resistance in 2018. 
Of those, there were 187,000 reported cases of either rifampicin-resistant TB (RR-
TB) or multidrug-resistant TB (MDR-TB). An estimated 11,600 individuals were 
also predicted to have extensively drug-resistant TB (XDR-TB), defined by 
resistance to not only isoniazid and rifampin, but also any fluoroquinolone and 
injectable second-line drugs (i.e., amikacin, kanamycin, or capreomycin) (6). 
Treatment for individuals with RR-TB and MDR-TB is longer, more toxic, and more 
expensive. Compared to an average of forty dollars per person for a 6-month 
regimen of first-line drugs, the cost to treat antibiotic resistance is over one 
thousand dollars (1). Combined with other healthcare costs, an average of 
$110,900 was spent to treat and manage one antibiotic-resistant tuberculosis 
patient, three times higher than that of an antibiotic-susceptible TB case (7). In 
addition, it is estimated that only 70% of new cases of active TB were actually 
reported in 2018, leaving 30% undiagnosed, untreated, and capable of transmitting 
Mtb or even drug-resistant Mtb (8). The extreme biological, social, and economic 
burden emphasizes the rising threat from TB and the need for researchers and 
funders to collaborate efforts in developing higher efficacy antibiotics and a more 
effective TB vaccine. 
Historically, vaccines have been the most cost-effective intervention against 
infectious diseases. The development of an effective vaccine against TB, however, 
has been much more challenging. The only licensed prophylactic vaccine for TB 
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prevention is the Bacillus Calmette–Guérin (BCG, an attenuated strain of 
Mycobacterium bovis) vaccine. The BCG vaccine has been used widely since 
1921 and is currently used to prevent severe forms of TB in children, tuberculosis-
induced meningitis, and reduce the risk of childhood dissemination (9). However, 
vaccine performance remains disappointing and inconsistent in adults. Despite 
controversy, studies reported its inefficiency in high TB burden regions (10-12). In 
fact, BCG is not recommended for use in the US (13) with the exception of  
healthcare or humanitarian workers traveling to areas with MDR-TB (14). There is 
currently no approved prophylactic or post-exposure treatment that is effective in 
preventing pulmonary TB, the form of the disease that is of public health concern. 
Many vaccine studies in animal models exhibited encouraging early bacterial 
burden control but did not affect survival and failed to achieve sterilizing immunity 
(15-17). Interestingly, individuals successfully treated for active TB are not 
protected from Mtb reinfection and do not develop sterilizing immunity (18). This 
raises the question of why immunity elicited by either vaccination or natural 
infection fail to provide protection. Therefore, it is necessary to understand 
pathogenesis and what constitutes protective immunity against Mtb in order to 






B. Mycobacterium tuberculosis Infection and Pathogenesis  
Dr. Robert Koch discovered an acid-fast, rod-shaped, slow-growing bacillus 
subsequently named Mycobacterium tuberculosis (Mtb) in 1882 (19, 20). The only 
ecological niche of Mtb is humans, and transmission is from people with active TB 
to other people via infectious aerosols (i.e., cough). Mtb primarily infects 
phagocytes, particularly resident alveolar macrophages in the lung, where it 
survives and replicates to establish a very successful niche within infected hosts 
(21, 22). Recruitment of other immune cells leads to the aggregation and formation 
of granulomas, a hallmark of TB. Diverse architectures of granulomas seen in 
humans (23) and experimental animal models (24, 25) contribute to differential 
hypotheses as to whether granulomas are beneficial to the Mtb bacterium by 
spatially restricting the access of protective cells or beneficial to the host by 
containing Mtb and restricting dissemination. Recent studies suggest that the local 
spread of actively dividing mycobacteria is facilitated during early granuloma 
formation (26, 27). Interestingly, individual granulomas within the same infected 
animal manifested independent fates with respect to bacterial growth (i.e., 
permissive vs. restrictive environments) (28).  
Mtb typically affects the lungs (pulmonary TB) but can also disseminate to 
other organs (extrapulmonary TB) via the bloodstream and cause meningitis, 
enteritis, pyelonephritis, and occasionally infiltrates the bone marrow (29). Among 
individuals infected with Mtb, the majority have latent TB infections (LTBI) and do 
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not progress to active TB disease. LTBI patients have a 5-20% lifetime risk of 
reactivation, and the development of active pulmonary tuberculosis is greatest in 
the first 2 years after infection (30). Interestingly, some household contacts of 
active TB patients have never converted their Tuberculin Skin Test (TST: type IV 
hypersensitivity reaction to the tuberculin antigen, indicating prior exposure or 
infection) (31) or Interferon Gamma Release Assays (IGRA: IFNg secretion 
response by Mtb-specific T cells as indication of Mtb infection) (32). This clinical 
population is termed “resisters” and could represent successful immune responses 
in preventing or clearing infection. However, additional studies—including more 
accurate diagnostic tests—are required to understand this interesting subset of 
individuals. 
Overall, it appears that the host immune system is mostly able to contain 
Mtb infection successfully, with a small percentage of individuals developing 
disease, which may be a sign of incompetence of host immune responses, an 
immune evasion strategy, or Mtb-human coevolution. Gaining a better 
understanding of previous and current global TB prevention efforts (including 13 
vaccine candidates and 23 combination drug regimens that are in clinical trials) 
could transform the future of TB prevalence. Next, I will discuss the immunological 





Immunity to Tuberculosis 
C. Immune Responses to Tuberculosis 
Upon Mtb infection, innate immunity is the first line of defense, recruiting 
inflammatory cells to the lung before the initiation of adaptive immunity. The main 
players of innate immunity consist of resident alveolar macrophages, monocyte-
derived macrophages, dendritic cells, and neutrophils. There is also growing 
knowledge of unconventional, innate-like T cells that interact with nonpolymorphic 
antigen-presenting molecules including CD1a, CD1b, or CD1c-restricted T cells 
(33), CD1d-restricted invariant natural killer T (iNKT) cells (34), and MR1-restricted 
mucosal-associated invariant T (MAITs) cells (35), all of which participate in the 
immune response to Mtb. The recognition of Mtb infection by macrophages results 
in the optimal production of pro- and anti- inflammatory cytokines to recruit, 
activate, and differentiate other innate and adaptive cell types. A disruption in the 
balance of pro- and anti-inflammatory cytokines can lead to detrimental effects on 
the host (36). Although macrophages can kill Mtb by reactive oxygen intermediates 
(ROI), reactive nitrogen intermediates (RNI) and efferocytosis (37, 38), they cannot 
effectively clear the infection. Instead, the initiation of granuloma formation by 
innate immunity (39) and subsequent recruitment of adaptive immunity players are 
necessary to control the infection. 
The recruited adaptive immune response consists of CD4 and CD8 T cells. 
CD4 and CD8 T cells are both required for protective immunity against Mtb in the 
mouse model (40). Importantly, the kinetics of Mtb-specific T cell responses are 
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delayed in comparison to other viral or bacterial infections. In contrast to detecting 
the T cell responses within 3-5 days of a viral infection, adaptive immune 
responses to Mtb infection do not appear at the site of infection until 11 days post-
infection in mice (41) and 42 days post-exposure in humans (42). This delay is due 
in part to the need for live Mtb bacteria to transport from the lungs—the site of 
infection—through infected dendritic cells (DCs) to mediastinal lymph nodes 
(MDLN: lung-draining LN) where bacterial antigens are generated (41, 43, 44). 
CD4 T cells are subsequently primed and activated in MDLN before migrating to 
the lungs. Interestingly, the migratory Mtb-infected DCs are inefficient at activating 
CD4 T cells, and the uninfected DCs are the cells that uptake the released proteins 
to process and activate CD4 T cells (45). Studies in mice with different genetic 
backgrounds and susceptibilities have helped to elucidate that earlier T cell 
activation in the MDLN is associated with superior control of Mtb in the lungs (41). 
CD4 T cells are required for control of tuberculosis in mice (40), cattle (46), 
nonhuman primates (47), and humans, as shown in HIV patients who have a 
reduced number of CD4 T cells (48). In addition, interferon-gamma (IFNg) 
production and secretion by CD4 T cells has been repeatedly shown to be critical 
in limiting bacterial growth and is therefore considered part of the central dogma 
of how Mtb infection is controlled (43, 49). For example, IFNg can activate 
macrophages and their apoptosis to kill Mtb (50). Furthermore, patients with 
Mendelian susceptibility to mycobacterial diseases (MSMD) harboring mutations 
in the IFNGR1 or IFNGR2 genes, which encode IFNg receptors, are more 
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susceptible to mycobacterial diseases (51). However, IFNg production does not 
always correlate with protection against TB. Though causation has not been 
shown, increased numbers of IFNg-secreting T cells are more correlated to TB 
disease burdens than to protection in mice (52). Higher numbers of IFNg-secreting 
T cells in humans were also associated with disease progression to active TB (53). 
When CD4 T cells engineered to produce larger amounts of IFNg were adoptively 
transferred, mice displayed worse outcomes (54). These contradictory results with 
IFNg challenge the central dogma and suggest that there are other protective 
mechanisms that contribute to the protection mediated by CD4 T cells in addition 
to the essentiality of IFNg. 
In addition to IFNg, tumor necrosis factor a (TNFa) is an essential 
multifunctional pro-inflammatory cytokine produced by myeloid cells, as well as by 
CD4 and CD8 T cells, which is essential for control of Mtb infection in animal 
models and in humans (55-57). LTBI patients have a higher risk of developing 
active TB when undergoing anti-TNFa treatment for autoimmune diseases. 
However, similar to IFNg, active TB patients contain a higher frequency of CD4 T 
cells that produce TNFa than patients with LTBI (58), suggesting a positive 
correlation of TNFa with bacterial burden.  
The majority of the T cells from diverse host genetic backgrounds are 
specific to a small subset of peptides among thousands of antigen-derived 
peptides. This selection results in immunodominant antigens. Several 
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immunodominant antigens for both class I and class II MHCs have been identified 
in the murine TB model, including Ag85a, Ag85b, CFP10, ESAT6 and TB10.4 (59). 
T cell responses to these antigens are also frequently detectable in Mtb-infected 
people and some are used in TB immunodiagnostic tests (60). Intriguingly, 
immunodominant antigen-specific CD4 and CD8 T cells do not necessarily 
represent an effective immune response. In rhesus macaques, induction of IFNg-
producing T cells by an adenovirus vaccine expressing Ag85A along with the 
immunodominant Mtb antigens Ag85B and TB10.4 did not protect from Mtb 
infection (61). Similarly, the MVA85A vaccine, which uses the immunodominant 
antigen Ag85A, induced a high amount of IFNg secretion (62) and polyfunctional T 
cells (63) in human subjects, but failed to provide protection (64). Taken together, 
IFNg and immunodominant antigen-specific T cells have been used as surrogates 
for responsive immunity against Mtb infection but may or may not correlate to 
protection. 
In addition to delaying the initiation of adaptive immune response, Mtb 
successfully establishes a chronic infection, which suggests continuous Mtb 
antigen production and immune stimulation. This constant antigen stimulation 
drives ESAT6-specific CD4 T cells to terminally differentiate and be retained in the 
pulmonary vasculature, resulting in a decreased capacity to provide protection 
compared to CD4 T cells in the lung parenchyma (65-67). However, this ESAT6-
specific response is a selective occurrence as Ag85B antigen is downregulated by 
Mtb and Ag85B-specific CD4 T cells do not exhibit dysfunctions (68) (further 
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discussion in section G: Immune Evasion Mechanism). Pulmonary T cells also 
express cell surface markers consistent with an exhausted phenotype (increased 
inhibitory receptors TIM3, PD-1, LAG3, 2B4) and function (lowered capacity to 
produce multiple cytokines) during the chronic infection phase in mice (69). 
Chronic infection and dysfunctional CD4 T cell responses may contribute to the 
inability of the immune responses to clear Mtb infection. 
 
D. The underappreciated role of CD8 T cells in TB Immunity 
Different models including antibody depletion in mice and nonhuman 
primates, along with mouse models with defects in class I MHC presentation (e.g., 
b2m knockout, TAP knockout, and H-2 KbDb double knockout) have shown that 
CD8 T cells are essential for optimal control of Mtb infection (40, 70-73). The 
appreciation of CD8 T cells’ contribution to protection, however, is masked by the 
importance of CD4 T cell functions; CD4 T cells help in priming CD8 T cells, 
recruiting CD8 T cells to the site of infection, and generating recall responses (40, 
74-78). Memory CD8 T cells have been shown to be important during TB (79, 80), 
suggesting that CD8 T cells may provide better protective roles during the chronic 
phase of infection. This notion is supported by a latent TB study where aerosol-
infected mice were antibiotic-treated before permitting bacterial growth and 
subsequently depleting T cells (81). CD8 T cell depletion during chronic infection 
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led to a significant increase in bacterial burden, whereas depletion of CD4 T cells 
did not, indicative of CD8 T cell-mediated killing.  
Cytotoxicity and cytokine production are the main effector functions CD8 T 
cells utilize to clear pathogens. Cytotoxic T lymphocyte (CTL) activities consist of 
cytotoxic granules such as perforin and granzyme, Fas/FasL (CD95/CD95L) 
pathway and cytokine secretion. During Mtb infection, CD8 T cells use all three 
mechanisms of cytotoxicity in vivo to induce apoptosis, the aforementioned 
efferocytosis, and killing of Mtb infected target cells (38, 82-84). In addition to 
perforin, which is required to restrict Mtb growth by murine CD8 T cells (83), 
cytotoxic granules in humans and nonhuman primates also contain granulysin that 
can directly kill Mtb in vitro (85). Importantly, mice with CD95L and perforin 
deficiencies are more susceptible to Mtb infection (86, 87), highlighting the 
importance of cytotoxic pathways for immunity to tuberculosis.  
In the absence of CD4 T cells, IFNg levels in the lungs were unaffected (88), 
and CD8 T cells were shown to increase their proportion of IFNg producers in 
chronic infection (89), suggesting CD8 T cells produce more IFNg in compensation. 
While IFNg secretion by CD8 T cells can activate macrophages and protect mice 
from Mtb infection in the absence of CD4 T cells (90), it cannot durably substitute 
CD4 T cells for protection (88). Together, CD8 T cells have been categorized as 
either IFNg-secreting cells or CTLs during Mtb infection (91), but which CD8 T cell 
functions to provide bacterial control is unclear (83, 85, 90, 92). Thus, CD8 T cells, 
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in concert with other cells of host immune response, collaborate and contribute to 
the optimal control of TB. A better understanding of the role of CD8 T cells in 
controlling TB is needed to develop a more effective vaccine. 
 
E. Current Vaccine Development and T cell Recognition 
The incompetence of BCG is thought to be a result of many factors 
including: (a) the genetic diversity of both BCG and Mtb strains prevalent 
throughout the world; and, (b) the genomic and antigenic differences between BCG 
and Mtb. Over 20% of known human CD4 and CD8 T cell epitopes in the Mtb 
genome are deleted from BCG genome including the immunodominant antigens 
ESAT6 and CFP10 (93). However, antigen loss and sequence variation alone are 
insufficient to account for the limited efficacy of BCG.  
The current strategy to design vaccine candidates aims at eliciting antigen-
specific T cell responses using immunodominant antigens as targets. For example, 
the MVA85A vaccine expresses the Mtb antigen 85A (Ag85A), an abundant 
secreted protein of Mtb. MVA85A induced high-frequency Ag85A-responsive T 
cells that produced IFNg, TNFa, IL-2, and/or IL-17. Using IGRA conversion as an 
indication of Mtb infection, the researchers reported that MVA85A failed to prevent 
new infections in both HIV-infected adults and healthy infants who previously 
received BCG (64, 94). On the other hand, the M72/AS01E vaccine, which 
employs the same strategy but uses Mtb antigens MTB32A and MTB39A, provides 
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54% protection against active pulmonary tuberculosis disease to HIV-negative 
adults with latent Mtb infection in phase IIb clinical trials (95, 96). Together, these 
studies raise the question of how one could define the protective T cell subsets to 
better design clinical trials and improve upon the 54% protection. 
There are a few confounders I could identify in vaccine studies. First, the 
measurements of antigen recognition were done with the assumption that 
antigens, especially immunodominant antigens, are presented by infected cells; 
hence, all antigen-specific T cells should recognize infected cells. Since CD4 T 
cells have been shown to require direct contact to recognize and limit intracellular 
Mtb (97), there is a disconnect in most studies which use peptide or protein as a 
stimulant, rather than Mtb-infected cells themselves. Secondly, while there is no 
known immune correlate of protection against tuberculosis, IGRA assays use IFNg 
as a readout of responsiveness and a surrogate for recognition of infected cells. 
IFNg and other cytokine secretions by CD4 and CD8 T cells can be stimulated by 
non-cognate (cytokine-driven) or cognate (T cell receptor-dependent) interactions, 
and indirect recognition through cytokine stimulation may not lead to clearance of 
infected cells. This is supported by an intravital imaging study that showed not all 
antigen-specific T cells interact with granulomas (98). Lastly, among hundreds of 
identified human antigens, the use of two antigens in the M72/AS01E vaccine are 
encouraging. While this work assumes that either MTB32A or MTB39A or both are 
presented by infected cells, identification of other antigens presented by infected 
cells could improve T cell responses and provide full protection to all populations. 
14 
 
Despite the necessary multifunctional effector roles of CD4 and CD8 T cells, 
immunocompetent animals can only maintain latency, containing but not 
eradicating Mtb infection. Whether humans can eliminate Mtb, however, is 
debatable. Recent reports suggest co-evolution of Mtb and humans is the 
consequence of successful immune evasion mechanisms employed by Mtb. 
Studying how Mtb subverts and adapts in response to host immunity will further 
enhance our understanding toward the development of strategies to eliminate Mtb. 
 
Mycobacterium tuberculosis Evolution and Evasion Mechanisms 
F. Evolutions and Transmission of Mtb Clinical Isolates  
The connection between our human ancestors and Mtb is long established. 
Some studies suggested Mtb coexisted with humans for 6,000 years (99, 100) 
while one study speculated back as many as 3 million years (101). Given that Mtb 
is a human obligate pathogen without an environmental or animal reservoirs, all 
Mtb adaptations are presumably through selections by human immune responses. 
The long-standing interaction—whereby Mtb infection stimulates inefficient 
immunity—reflects an evolutionary arms race that needs to allow survival of both 
the pathogen and its host.  
Mtb bacteria that are isolated from sputum or resected lung of tuberculosis 
patients are referred to as clinical isolates. New technology has facilitated the study 
of Mtb evolution through the sequencing of clinical isolates. This led to the 
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categorization of Mtb into lineages based on gene clusters, such as TbD1 deletions 
(102). Despite the historical belief that Mtb strains are highly uniform because of 
their slow growing nature and lack of mutation, clinical isolates of virulent Mtb that 
infect human populations show significant heterogeneity (103). Some Mtb lineages 
are more globally distributed and contain more variable T cell epitopes, suggestive 
of interactions with diverse populations and/or evidence of immune escape. Some 
lineages have strong geographical restriction (104, 105), which could represent 
the preference in host-adaptation, limited mobility of the infected population or its 
more recent appearance.  
Distinct ethnicity and MHC alleles have previously been reported to impact 
T cell responses in various infectious diseases including Hepatitis B (106), 
Hepatitis C (107) and HIV (108). Given that class I MHC is the most polymorphic 
allele in the human genome (109), this relationship may reflect a host and 
pathogen co-adaptation, which in turn drives diversification in both MHC and 
pathogen. Therefore, Mtb genetic diversity and reciprocal host tolerance to 
mycobacterial infections are important interplaying components, contributing to 
disease trajectory and transmission patterns.  
Unlike many pathogens that spread during an asymptomatic state, Mtb 
induces human disease, displayed as a cough and fever, and transfers to different 
hosts. The transmission of Mtb, therefore, depends on pulmonary disease, 
showing a direct correlation of virulence and transmission. In addition, as opposed 
to many viruses whose antigenic sequences are variable for immune escape, the 
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vast majority of antigens encoded in the Mtb genome are conserved (110, 111). 
This unique antigen conservation has been predicted to benefit the bacteria’s 
ability to exploit adaptive immune responses, potentially through inflammatory lung 
and tissue damage. The absence of escape mutations in Mtb genomes could 
represent a well-adapted, inefficient immunity that Mtb prefers to prevent the 
clearance of infection.  
 
G. Immune Evasion Mechanisms 
Mtb is a remarkably successful pathogen that utilizes multiple mechanisms 
for evading and subverting immune responses. Given that Mtb infects professional 
antigen-presenting cells and CD4 T cells are essential to limit Mtb growth, multiple 
mechanisms to perturb innate immunity (26) and inhibit class II MHC presentation 
and CD4 T cell recognition (112) are employed by Mtb. Mtb replicates in early 
phagosomes, inhibits phagosome maturation (113) and lysosomal fusion (114), 
and evades the immune system. The mycobacterium also induces damaging type 
I interferon or excessive TNFa secretion (115, 116) to boost its early survival and 
delay adaptive immunity (117). 
Mtb utilizes various strategies to hamper class II MHC presentation such as 
inhibiting class II MHC molecule intracellular trafficking (118) and blocking IFNg-
mediated upregulation of class II transactivator (CIITA, the master regulator of 
MHC II genes), which controls genes in the class II MHC pathway in mice and 
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humans (119-121). (Side note: Mtb cytokine signaling interference may help 
explain why IFNg is not correlated to protection in TB). Mtb also diverts its secreted 
antigens from the class II MHC pathway to the extracellular space through 
vesicular transport (122, 123). This process, interestingly, enhances CD4 T cell 
priming and recognition of uninfected cells that take up the exported antigen (45), 
but evades the direct recognition of infected cells. Blockage of the motor 
component leads to decreased antigen export, increased antigen presentation of 
Mtb-infected cells to ESAT6- and Ag85B-specific CD4 T cells, and enhanced 
bacterial control both in vitro and in vivo (122).  
Recently, the Mtb-encoded PE_PGRS47 gene was discovered to play a 
role in class II MHC inhibition, and its deletion resulted in Mtb attenuation (124). 
PE_PGRS47 was also reported to disrupt autophagy in infected macrophages, 
supporting roles of autophagy in class II MHC presentation of mycobacterial 
antigens and Mtb evasion (125). Another study reported a role of the Mtb-secreted 
molecule EsxH (or TB10.4) in inhibiting class II MHC presentation (113). The EsxH 
protein was shown to directly bind Hrs, a component of the endosomal sorting 
complex required for transport (ESCRT) machinery in human and murine cells, 
thereby dysregulating phagosomal maturation and antigen processing (126). EsxH 
overexpression enhanced (while its deletion improved) Mtb-specific CD4 T cell 
activation. EsxH-deficient mycobacteria were also attenuated in 
immunocompetent mice, but not in CD4 T cell-deficient mice, indicating EsxH 
interferes with CD4 T cell activation. In addition, Mtb has also been shown to 
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regulate its gene expression in vivo to limit T cell responses. Ag85B transcript 
expression was high during the initiation of Mtb infection in the lungs and 
decreased later, leading to reduced activation of Ag85B-specific CD4 T cells (127). 
Conversely, forced expression of Ag85B leads to the attenuation of the Mtb strains 
because of better antimicrobial activity of Ag85B-specific CD4 T cells in vivo (127). 
Last, but not least, Mtb inhibits bacterial clearance by macrophages. Mtb 
induces infected macrophages to produce lipoxin A4 (LXA4), prevent 
prostaglandin E2 (PGE2)-dependent plasma membrane repair, and undergo 
necrosis rather than apoptosis (128). While apoptotic cells can be phagocytosed 
by uninfected cells (38), necrotic cells allow for the escape of Mtb which can then 
infect other cells and disseminate the infection (129). The upregulation of LXA4 
delays the priming of T cells and therefore promotes the establishment of 
persistent infection (128). In turn, Alox5 deficient mice (which cannot make LXA4) 
generated antigen-specific T cells earlier, enhanced effector functions and 
decreased bacterial burden (130). In parallel, a proapoptotic DnuoG Mtb appears 
earlier in the mediastinal lymph node (131), leading to earlier priming of antigen 
specific CD4 T cells (132). 
These examples—among many other studies—have shown that Mtb 
manipulates host immune responses at many levels, suggesting that there are 




H. Evasion of CD8 T cell immunity 
Less is known about how CD8 T cells respond during infection and whether 
Mtb evades CD8 T cell recognition. This could be because: (a) other protective 
immune components, such as CD4 T cells, mask the influences of CD8 T cells; or, 
(b) Mtb suppresses CD8 T cell roles. One report showed that mycobacterial 
antigens localize to phagosomes and segregate from cytosolic class I MHC 
molecules (133), providing evidence Mtb averts class I MHC antigen presentation 
for TCR-mediated CD8 T cell recognition. Furthermore, apoptotic vesicles from 
Mtb-infected macrophages activated CD8 T cells in vivo, and vaccination using the 
vesicles alone was able to provide protection (134). This supports the previous 
finding that inhibiting apoptosis decreases CD8 T cell activation (133). If, similar to 
class II MHC, Mtb-infected cells themselves do not present antigen, but rather the 
bystander uninfected cells do so by acquiring antigens from apoptotic cells (45), 
this would imply Mtb distracts CD8 T cells from directly recognizing and killing Mtb-
infected cells in vivo. 
 Though not reported during Mtb infection, many viruses such as 
herpesviruses (135, 136) and cowpox viruses (CPXV) (137), evade CTL response 
by inhibiting class I MHC antigen presentation via retaining class I MHC molecules 
in the endoplasmic reticulum and preventing peptide loading (138). In addition, the 
CPXV-specific CTL response in C57BL/6 mice exhibits an immunological 
phenomenon called immunodominance where a single antigen, B8, dominates 
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(139), similar to Mtb-specific CD8 T cell response in Mtb-infected C57BL/6 (140, 
141). This process was reported to hamper the development of successful 
vaccines because of lacking efficient effector functions (142). Deleting the 
immunodominant epitope from the virus gives rise to compensation and 
domination by subdominant epitopes instead (143, 144), suggesting an inhibition 
of subdominant epitopes by an immunodominant epitope. This phenomenon is 
termed immunodomination and also occurs as a mechanism by which memory 
responses inhibit naïve CD8 T cell responses (145). Interestingly, a recent study 
indicated that CD8 T cell immunodomination during primary CPXV infections was 
not affected by viral class I MHC inhibition (137).  
Taken together, Mtb utilizes a variety of mechanisms for immune evasion, 
some of which implicate Mtb’s capability to directly avoid detection, and therefore 
enhance its survival. Given that CD8 T cells are essential in controlling Mtb 
infection (71) and there are many reports of CD8 T cell evasion in viral immunity 
(136, 137), to understand whether the suboptimal contribution of CD8 T cells is 
due to Mtb modulation of CD8 T cell recognition and functions is of critical value. 
We next discuss the immunodominance phenomenon by TB10.4 protein 
during Mtb infection. As immunodominance has been shown to interfere with the 
generation of desired immune responses through successful vaccination (142), 
this emphasizes that evaluating the pre-existing immunity is crucial to predict the 
outcome of vaccine responses.   
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esxH gene, TB10.4 protein, and TB10.4-specific T cells 
Mtb secretion systems are crucial for Mtb pathogenesis and virulence, and 
their antigenicity are important to understand host and pathogen interactions (146). 
ESAT6 secretion (ESX, also known as type VII secretion) systems are Mtb 
secretion systems named after the first identified substrate, the 6 kDa early 
secretory antigenic target (ESAT6, also known as EsxA). ESX systems and their 
secretion substrates are the main players of Mtb pathogenicity (147). Of the 5 ESX 
systems in Mtb (ESX-1 through ESX-5), ESX-1 was the first to be discovered from 
genomic analysis of the M. bovis strain of BCG vaccine where a large deletion of 
Region of Difference 1 within the esx1 operon caused attenuation of the strain 
(148). ESX-1, the most characterized secretion system in Mtb, is essential for 
microbial resistance and host immune evasion. EsxA or ESAT6, in addition to 
being described as a substrate for ESX-1 and a cytolytic virulence factor of Mtb 
(149), is a potent T cell antigen that has been used in many vaccines (150, 151). 
Similarly, ESX-3 is crucial for Mtb viability and pathogenesis, but much less is 
known. The ESX-3 secretion system is encoded within the esx3 operon and plays 
both iron-dependent and -independent roles in Mtb pathogenesis and survival 
(152). The iron and zinc acquisition and metal homeostasis roles of ESX-3, 
however, depend on host genotypes. Since different hosts have varied iron 
availability, this suggests that Mtb uses ESX-3 to counteract host defense 
mechanisms in restricting iron nutrients. esxH, or Rv0288 in the esx3 operon, 
encodes for a secreted protein EsxH or TB10.4 that is co-expressed with its partner 
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EsxG from the Rv0287 gene within the same operon (152). Mycobacteria with 
esxH deficiency exhibit an absence of growth in vivo and require iron 
supplementation to grow in culture (152). As described earlier (section G: Immune 
Evasion Mechanisms), the EsxH/TB10.4 protein plays a role in disrupting class II 
MHC presentation through ESCRT (126) and is the protein of interest.  
TB10.4, similar to ESAT6, is an antigenic protein that generates TB10.4-
specific T cell responses in human and animal models (153-158) among hundreds 
of other epitopes that have the potential for recognition by CD8 T cells (59, 159). 
Axelsson-Robertson et al. have extensively studied human class I MHC, which is 
the most polymorphic molecule in the human genome, in the context of TB10.4-
responsive CD8 T cells using Mtb-infected human PBMCs and immobilized 
recombinant class I MHCs (153-155). The researchers have studied MHC 
molecules in Caucasians, Asians and Africans including the human leukocyte 
antigen (HLA)-A*30 family which is one of the most frequent allele families of 
African background individuals and found numerous candidate epitopes from 
TB10.4. 
In addition to class I MHC diversity, esxH polymorphisms were reported 
whereas other antigenic regions were hyperconserved (110). In this study, only a 
limited number of Mtb clinical isolates were sequenced, so one could argue that 
the comparison to the H37Rv lab strain as “wild-type” added to the bias in the 
interpretation of the results. The follow-up study, however, used an unbiased 
computational approach with a larger set of Mtb genome sequences, and esxH 
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was again identified as one of the top polymorphic genes (111). The naturally 
occurring single amino acid exchanges in the TB10.4 protein included A10T, 
G13D, S27N and A71S (110), all of which are part of previously reported CD8 T 
cell epitopes (153, 155). This antigenic variation may impact antigen presentation 
and subsequent T cell recognition. 
Following aerosol infections, C57BL/6 mice generate 30-50% of pulmonary 
CD8 T cells specific for a single epitope, H-2Kb-restricted TB10.44-11 (156, 160-
162). H-2Kd-restricted TB10.420-28 CD8 T cells are also elicited at a high frequency 
in Mtb-infected BALB/c mice, along with I-Ad-restricted TB10.474-88-specific CD4 T 
cells (157, 158). Taken together with data from human studies, TB10.4 is an 
immunodominant antigen, which makes it an attractive target for vaccine 
development with the assumption that Mtb-infected cells are antigen-presenting 
cells responsible for these large responses to TB10.4 antigen. As a side note, the 
secreted immunodominant antigens of Mtb are likely processed through the cross-
presentation pathway (133, 163) and blocking bacterial secretion has prevented 
the priming of Mtb-specific CD8 T cells (162). 
Despite the ability to lower bacterial burdens in CD4 and CD8 T cell deficient 
mice in the adoptive transfer model (160, 161), TB10.44-11-specific CD8 T cell 
responses elicited by vaccination do not mediate protection in immunocompetent 
mice (160, 164). In particular, TB10.4-immunized animals generated larger and 
earlier TB10.4-specific responses, but the vaccinated mice did not exhibit more 
protective immune responses. Unvaccinated mice were able to catch up and 
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displayed the same number of TB10.4-specific CD8 T cells by the peak of the 
infection (160). In addition, the AERAS-402 vaccine, which uses TB10.4 as an 
antigen, also failed to elicit protective immunity in humans (61, 165). 
An explanation for the failure of TB10.4-specific CD8 T memory cells to 
mediate protection may be due to the failure of TB10.44-11-specific CD8 T cells to 
recognize Mtb-infected macrophages as reported by our group (166). We have 
begun to gain some insights as we were able to detect TB10.44-11-specific CD8 T 
cell recognition when using Listeria monocytogenes expressing TB10.4 in place of 
Mtb. We hypothesize that Mtb uses TB10.4, which does not present on Mtb-
infected cells, as a decoy antigen to distract host immunity from other protective 
antigens for immune evasion. Together, the naturally occurring variations in 





The majority of Mtb epitopes recognized by human T cells are encoded by 
regions of the Mtb genome that are hyperconserved, excluding esxH. As Mtb-
specific T cell responses are required for protective immunity, it is critical to 
understand the paradoxical notion that Mtb could benefit from T cell immunity.  
In this dissertation, I employ immunological and bacterial genetic 
approaches to investigate how Mtb exploits its antigenic polymorphisms to evade 
host adaptive immune responses and establish a successful infection. In particular, 
we hypothesize that polymorphisms in TB10.4 could modulate immunodominant 
CD8 T cell responses which Mtb may develop as an immune evasion strategy. 
Chapter II addresses the recognition of Mtb-infected cells by H-2Kd-restricted 
TB10.420-28-specific and H-2Kb-restricited MTB32a309-318-specific CD8 T cells to 
determine whether other class I MHC, or only TB10.44-11, epitopes could act as 
decoys. Chapter III focuses on antigen-specific T cell responses to polymorphic 
epitopes and the clinical Mtb isolates containing these polymorphisms. Chapter IV 
focuses on the cause of antigenic shift described in Chapter III. Finally, Chapter V 
investigates the ability of polyclonal T cells elicited by Mtb infection in vivo to 
recognize Mtb-infected macrophages. A discussion in Chapter VI of data 
presented will review the possible areas of improvement and remaining questions 
for further investigation. 
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The results and analyses in this dissertation will enhance the understanding 
of Mtb infections with naturally occurring polymorphic immunodominant antigens 
and the consequences on antigen-specific T cells responses and disease 
outcomes. This work directly impacts the strategies for vaccine design and 
development against tuberculosis and implicates a need for better comprehension 
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 Immunodominant Mtb-specific CD4 and CD8 T cell responses, which signify 
a selection of few antigens for the generation of T cell immunity, are the primary 
targets of vaccine development. Despite robust and persistent Mtb-specific CD8 T 
cell responses during Mtb infection, less is understood regarding why CD8 T cells 
contribute minimally to protection. In this chapter, I assess the ability of three 
dominant Mtb-specific CD8 T cells to recognize Mtb-infected macrophages in vitro 
in comparison to Mtb-specific CD4 T cells. The CD8 T cells are specific to: (1) H2-
Kb/TB10.44-11, (2) H2-Kd/TB10.420-28, and (3) H2-Kb/MTB32a309-318 Mtb epitopes. 
Compared to the capability of Ag85b240-254-specific CD4 T cells in recognizing Mtb-
infected macrophages, the Mtb-specific CD8 T cells neither recognized Mtb-
infected macrophages nor restricted Mtb growth. We propose that 
immunodomination could act as a decoy mechanism for Mtb immune evasion; by 
inducing a large response of CD8 T cells that cannot recognize Mtb-infected cells, 




 Mycobacterium tuberculosis (Mtb) infected 1.7 billion people globally and 
caused 1.5 million deaths in 2018 alone (1). While Mtb has demonstrated its 
capability to subvert host immune responses and establish its niche, CD4 and CD8 
T cells have shown their essentiality to control the infections in both human and 
animal models (40, 167). Yet, the functions of protective immunity are not well-
defined. Given that vaccination is the most effective infectious disease 
intervention, studies have focused on eliciting immunodominant T cell responses, 
anticipating their ability to mediate protection and prevent disease. This is based 
on the underlying assumption that immunodominant antigen-specific CD4 and 
CD8 T cells are primed by infected cells, therefore they should recognize and kill 
the infected cells.  
One protein of interest is TB10.4, encoded by esxH gene, an 
immunodominant protein which is a component of the AERAS-402 vaccine (61, 
165). Studies of Mtb-infected patients have shown several different epitopes from 
the TB10.4 protein elicit HLA-restricted CD8 T cells (153-155). In the murine 
model, 30-50% of CD8 T cells in the lungs of Mtb-infected C57BL/6 mice recognize 
the TB10.44-11 epitope (140, 160, 161), and 10-15% of CD8 T cells are specific for 
the TB10.420-28 epitope in infected BALB/c mice (157, 158). These data indicate 
that TB10.4 induces immunodominant CD8 T cell responses during Mtb infection. 
However, whether TB10.44-11-specific CD8 T cells can provide protection is 
unclear. Adoptive transfer of TB10.44-11-specific CD8 T cells into immunodeficient 
30 
 
mice reduced the bacterial burden (161), but successful vaccination and 
generation of TB10.44-11-specific CD8 T cells did not provide protection compared 
to mock-vaccinated control in immunocompetent mice (160). Given the dichotomy 
of these results, we hypothesize that TB10.44-11-specific CD8 T cells are unable to 
efficiently recognize Mtb-infected cells. In this chapter, we also investigate the 
capacity of TB10.420-28-specific CD8 T cells to recognize Mtb-infected cells. These 
responses will be compared to the ability of CD4 T cells to recognize infected cells 
by using P25, a CD4 T cell line specific for Ag85B; we have previously 
demonstrated its capability to recognize infected cells and suppress the growth of 
intracellular Mtb (166). 
Another protein of interest is MTB32A, encoded by Rv0125, which is part of 
the M72/AS01E vaccine that has had promising results in a phase IIb clinical trial, 
and is proceeding towards a phase III clinical trial (96). The MTB32A309-318 epitope 
is recognized by 2-5% of CD8 T cells in the lungs of Mtb-infected C57BL/6 mice 
(168), indicating it is a major response, although subdominant to the TB10.4 
protein. MTB32A309-318-specific CD8 T cells will be evaluated for their capacity to 
recognize Mtb-infected cells. 
IFNg secretion and the Mtb-Infected Macrophage ELISpot (MIM-E) assay 
(see (169), and Chapter V for a thorough discussion) will be used to assess T cell 
recognition of infected macrophages. This assay allows us to compare the 
recognition of antigens (i.e., in the form of proteins or synthetic peptides) versus 
Mtb-infected macrophages.  Here we determine whether antigen-specific CD8 T 
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cells, which are elicited by vaccination and can recognize peptide-loaded cells, 




Generation of H2-Kb-restricted TB10.44-11-specific TB10RgL, TB10RgR, 
TB10RgP, TB10Rg3 CD8 T cell lines 
To determine whether immunodominant TB10.44-11-specific CD8 T cells can 
recognize Mtb-infected macrophages, I generated TB10.44-11-specific CD8 T cell 
retrogenic mice named TB10RgL, TB10RgR, TB10RgP and TB10Rg3 (166).  We 
chose to use four different T cells, all specific for the same TB10.44−11 epitope to 
obtain T cell receptors (TCRs) representative of in vivo clonally expanded 
TB10.44−11-specific CD8 T cells from the lung of infected C57BL/6 mice (161). 
TB10RgL, TB10RgR, TB10RgP and TB10Rg3 CD8 T cells are all specific to the 
TB10.44−11 epitope but use distinct TCRs that encode related CDR3a and CDR3b 
regions (Figure 2.1A). We then derived TB10.44-11-specific CD8 T cell lines from 
TB10RgL, TB10RgR, TB10RgP and TB10Rg3 retrogenic mice by stimulating 
purified splenic CD8 T cells with TB10.44-11-pulsed irradiated splenocytes 
supplemented with IL-2. Stimulated cells were monitored for their proliferation and 
passaged following expansion. At 4 days post stimulation, TB10RgL, TB10RgR, 
TB10RgP and TB10Rg3 T cell lines expressed GFP (co-expressed with the TCRs 
as part of the retroviral vector) and their specific Va and Vb receptors(Figure 2.1B). 
TB10RgL T cell line was 47% Vb5+GFP+ and represented the lowest uniform 
population among four cell lines. At 3 weeks post-stimulation, TB10RgL and all 
other T cell lines were more than 98% positive for its specific Va and Vb receptors 
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(Figure 2.1C). The TB10.44-11-specific CD8 T cell lines were subsequently used in 
assays at 3-5 weeks post-stimulation and could be maintained in vitro by 







Figure 2.1: Generation of H2-Kb-restricted TB10.44-11-specific TB10RgL, 
TB10RgR, TB10RgP, TB10Rg3 CD8 T cell lines  
(A) TCRa and TCRb family with the sequences of CDR3a and CDR3b regions of 
TB10RgL, TB10RgR, TB10RgP, TB10Rg3 CD8 T cell lines. (B-C) Purified CD8 T 
cells from TB10RgL, TB10RgR, TB10RgP, TB10Rg3 retrogenic mice were co-
cultured with TB10.44-11-pulsed irradiated splenocytes with IL-2 supplement. (B) At 
four days post in vitro stimulation, each T cell line was stained for expression of 
CD8 and its specific Va and Vb: TB10RgL and TB10RgR with Vb5 antibody, 
TB10RgP with Vb4 antibody, and TB10Rg3 with Va2 antibody. Each T cell line 
was gated on CD8+ and subsequently GFP+ and Va/Vb+. (C) At three weeks post-




The H2-Kb-restricted TB10.44-11-specific TB10RgL, TB10RgR, TB10RgP and 
TB10Rg3 CD8 T cells do not recognize infected macrophages nor inhibit 
intracellular Mtb growth 
 TB10RgL, TB10RgR, TB10RgP and TB10Rg3 CD8 T cell lines were 
compared to the Ag85B241-256-specific (P25) CD4 T cell line. To evaluate their 
ability to recognize Mtb-infected macrophages, thioglycolate-elicited peritoneal 
macrophages (TGPM) were infected in vitro with H37Rv Mtb, and then co-cultured 
with each T cell line, with or without its cognate epitope (i.e., synthetic peptide). In 
the peptide-included condition, all T cell lines sensitively responded by secreting 
IFNg, measured by ELISA, demonstrating the specificity of TB10RgL, TB10RgR, 
TB10RgP and TB10Rg3 CD8 T cells to the TB10.44-11 epitope and P25 CD4 T 
cells to the Ag85B241-256 epitope (Figure 2.2A). However, only P25 CD4 T cells 
were able to recognize Mtb-infected macrophages in the absence of cognate 
peptide. We next asked whether the ability to recognize infected cells, as 
measured by IFNg production, correlated to the ability of each T cell line to restrict 
bacterial growth. We cultured respective T cell lines with infected macrophages, 
with or without their cognate antigens, for 96 hours before determining bacterial 
loads in comparison to the no T cell condition. Similar to their IFNg production, only 
P25 CD4 T cells were able to control bacterial growth without the presence of its 
cognate antigen (Figure 2.2B). 
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 Using multiple independent T cell lines with the specificity to a single 
TB10.44-11 epitope, we showed that TB10.44-11-specific CD8 T cells lines are 








Figure 2.2: TB10.44-11-specific CD8 T cells do not recognize Mtb-infected 
macrophages.  
C57BL/6 TGPMs were infected with H37Rv Mtb for 2 hours. (A) After 2 hours, 
bacteria were washed off. TB10.44−11 peptide and Ag85b240-254 peptide were added 
for 1 hour in the peptide-pulsed condition and subsequently washed off. TB10RgL, 
TB10RgR, TB10RgP, TB10Rg3, or P25 T cells were cocultured with uninfected, 
Mtb-infected, or peptide-pulsed TGPMs for 3 days, and supernatants were 
subsequently measured for IFNg by ELISA. (B) At one day post H37Rv infection, 
TB10.44−11 peptide and Ag85b240-254 peptide were added in “+” conditions, washed 
after 1 hour, and TB10.44−11-specific CD8 and P25 CD4 T cells were added 
respectively. CFUs were determined 96 hours post-coculturing. Results are 
representative of three experiments. Statistical testing was by one-way ANOVA, 





Generation of TB10.420-28-specific CD8 T cells by Trivax-TB10.420-28 
vaccination 
 We next sought to determine if the failure of TB10.4-specific CD8 T cells to 
recognize Mtb-infected macrophages was true for other epitopes or genetic 
backgrounds. As Mtb infection of BALB/c mice elicits an immunodominant CD8 T 
cell response for the TB10.420-28 epitope (157, 158), we determined whether 
TB10.420-28-specific CD8 T cells could recognize Mtb-infected macrophages. We 
generated TB10.420-28-specific CD8 T cells by vaccinating BALB/c mice using the 
Trivax strategy which consisted of anti-CD40 mAb, Poly(I:C) and a short synthetic 
epitope peptide (i.e., TB10.420-28 here) (170, 171). BALB/c mice were injected 
intravenously with Trivax-TB10.420-28 vaccine (160). Vaccinated mice were rested 
for 3 weeks before subsequent boosting with Trivax-TB10.420-28 and monitored for 
their generation of TB10.420-28-specific CD8 T cells (Figure 2.3A). At one week 
post-boost, 2.56% of splenic CD8 T cells from Trivax-TB10.420-28 mice were 
specific for H-2Kd/TB10.420-28 tetramer, and we obtained 1.67% tetramer+ cells 
after CD8 T cell purification (Figure 2.3B). The H-2Kd/TB10.420-28 tetramer+ CD8 T 
cells were of an activated phenotype, determined by high CD44 expression (Figure 
2.3B). The purified CD8 T cells were used in a recognition assay and stimulated in 
vitro to generate TB10.420-28-specific CD8 T cell line as described earlier. Three 
weeks after stimulation, the TB10.420-28-specific CD8 T cell line contained 70% H-
2Kd/TB10.420-28 tetramer-specific T cells with lower CD44 expression, indicating 







Figure 2.3: Generation of TB10.420-28-specific CD8 T cells.  
(A) Schematic representation of vaccination strategy used to generate TB10.420-
28-specific CD8 T cells. (B-C) Flow cytometry representation of H-2Kd/TB10.420-28 
tetramer staining of (B) ex vivo pre-purified and post-CD8-purified splenic cells at 
one week post-boost and (C) TB10.420-28-specific CD8 T cell line at 3 weeks post 
stimulation. Cells were gated on CD8 T cells and the activated state was 





The H2-Kd-restricted TB10.420-28-specific CD8 T cells do not recognize 
infected macrophages 
 We subsequently performed the MIM-E assay [Mtb-Infected Macrophage 
ELISpot (169)], to determine whether ex vivo H-2Kd-restricted TB10.420-28-specific 
CD8 T cells and the corresponding in vitro derived CD8 T cell line recognized Mtb-
infected macrophages. Here we used TGPM from CB6F1 mice (C57BL/6 x BALB/c 
F1), so we could compare the recognition by the Kd-restricted CD8 T cells with the 
I-Ab-restricted P25 CD4 T cell line. Among purified splenic CD8 T cells from Trivax-
TB10.420-28 mice, ~0.5% produced IFNg when stimulated with the TB10.420-28 
peptide (Figure 2.4A). Given that 1.67% were H-2Kd/TB10.420-28 tetramer+ (Figure 
2.3B), approximately 30% of TB10.420-28-specific CD8 T cells produced IFNg in 
response to its cognate epitope. However, IFNg was not detected in the Mtb-
infected macrophage condition (Figure 2.4A). The in vitro derived TB10.420-28-
specific CD8 T cell line with 70% H-2Kd/TB10.420-28 tetramer+ (Figure 2.3C) was 
also able to produce IFNg in response to its epitope but failed to produce IFNg 
when co-cultured with Mtb-infected cells (Figure 2.4B). In addition, only a small 
population of TB10.420-28-specific CD8 T cells recognized g-irradiated Mtb. P25 
CD4 T cell line recognition of Mtb infected cells indicated that Mtb-infected TGPMs 
were able to stimulate responses (Figure 2.4C). The data show that, in addition to 
TB10.44−11-specific CD8 T cells, TB10.420-28-specific CD8 T cells do not recognize 





Figure 2.4: TB10.420-28-specific CD8 T cells do not recognize Mtb-infected 
macrophages.  
Thioglycolate-elicited peritoneal macrophages (TGPMs) were obtained from 
CB6F1 mice for the MIM-E assay. In short, TGPMs were infected overnight with 
H37Rv and subsequently harvested, washed, and counted along with uninfected 
cells. Infected and uninfected TGPMs were plated on membrane ELISpot plates 
with irradiated Mtb, short peptides, or anti-CD3 antibody. (A) ex vivo Trivax-elicited 
TB10.420-28-specific CD8 T cells, (B) in vitro-derived TB10.420-28-specific CD8 T cell 
line, or (C) P25 CD4 T cell line were added and co-cultured overnight before 
following the manufacturer’s protocol for ELISpot development and counting. 
Results are representative of two experiments. 
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A subdominant H-2Kb-restricted MTB32a309-318-specific CD8 T cell does not 
recognize infected macrophages  
Since CD8 T cells lines specific for two different TB10.4 epitopes did not 
recognize Mtb-infected macrophages (Figure 2.2, 2.4), we sought to determine 
whether a different Mtb epitope recognized by CD8 T cells would recognize Mtb 
infected macrophages. We chose MTB32a because the protein is a component of 
the promising M72/AS01E vaccine candidate (96) and MTB32a309-318 epitope 
induces a subdominant CD8 T cell response during Mtb infection in C57BL/6 mice 
(168). We generated MTB32a309-318-specific CD8 T cell line by Trivax vaccination 
as previously described (Figure 2.3). One week post-boost, Trivax-MTB32a309-318 
elicited 18.4% H-2Kb/MTB32a309-318-tetramer+ among splenic CD8 T cells (Figure 
2.5A). Splenic CD8 T cells were purified for MIM-E assay and subsequent 
generation of MTB32a309-318-specific CD8 T cell line. Of note, MTB32a309-318-
tetramer+ population became 6.61% after CD8 purification, which we considered 
due to the purification antibody cocktail containing CD11c, a marker that can be 
expressed on activated T cells. After three weeks, MTB32a309-318-specific CD8 T 
cell line was over 90% H-2Kb/MTB32a309-318-tetramer+ (Figure 2.5B). Despite their 
ability to recognize cognate antigen, neither the Trivax-MTB32a309-318 elicited CD8 
T cells nor the MTB32a309-318-specific CD8 T cell line recognized Mtb infected cells, 
as measured by MIM-E or IFNg-secretion assays, respectively (Figure 2.5C-D). 
Furthermore, the recognition of g-irradiated Mtb by ex vivo vaccine-elicited 
46 
 
MTB32a309-318-specific CD8 T cells was much lower than by the MTB32a309-318-
specific CD8 T cell line. 
Here we showed that, in addition to TB10.44-11-specific CD8 T cells, neither 
TB10.420-28-specific CD8 T cells nor MTB32a309-318-specific CD8 T cells recognized 
Mtb infected macrophages despite their recognition of their cognate peptide and 
binding to the peptide-loaded MHC molecule (i.e., as measured by tetramer 
staining).  Thus, I have demonstrated that CD8 T cells specific for three distinct 
epitopes fail to recognize infected macrophages. We have not yet discovered any 
antigens that are presented by Mtb-infected cells and recognized by CD8 T cells. 
These data imply that dominant CD8 T cell responses are elicited by mechanisms 
other than direct priming by Mtb-infected cells and that Mtb directly suppress CD8 









Figure 2.5: Generation and recognition of MTB32a309-318-specific CD8 T cells.  
Flow cytometric analysis of H-2Kb/MTB32a309-318 tetramer staining of (A) ex vivo 
pre-purified and post-CD8-purified splenic cells at 1 week post-boost and (B) 
MTB32a309-318-specific CD8 T cell line at 3 weeks post stimulation. Cells were 
gated on CD8 T cells. (C) Trivax-MTB32a309-318 elicited CD8 T cells were used in 
MIM-E assay as described previously. (D) MTB32a309-318-specific CD8 T cell line 
was co-cultured with H37Rv-infected or uninfected TGPMs with indicated 
stimulations for three days. IFNg in the supernatants was subsequently measured 




T cell immunity is essential during Mycobacterium tuberculosis infection in 
both humans and mice (40, 167). CD4 T cells are vital to provide a protective role 
against Mtb infection, but less is understood regarding the role of CD8 T cells in 
protective immunity against tuberculosis. Correlates of protection and what classify 
an effective T cell response to Mtb are not well-defined and these confounding 
factors complicate the discovery toward an effective TB vaccine. 
In this chapter of my dissertation, I used IFNg secretion detected by ELISA 
and ELISpot to investigate the recognition of Mtb-infected macrophages by 
antigen-specific CD8 T cells. IFNg production, a common readout for recognition, 
can be stimulated by TCR-mediated interaction (cognate) and IL-12 and IL-18 
cytokines secreted by Mtb-infected cells (non-cognate) (172, 173). Although MHC-
mismatched antigen-presenting cells (APC) or MHC-blocking antibodies were not 
included as controls to verify MHC-restriction, the lack of recognition obviated the 
need for these controls. In addition, we have used anti-IL12 and anti-IL18 
antibodies (to block non-cognate recognition) along with KbDb deficient mice (to 
block cognate recognition) in establishing the MIM-E assay, and did not observe 
evidence of non-cognate CD8 T cell activation in these assays (169). 
Despite the persistence and immunodominance in the lungs of Mtb-infected 
mice, H-2Kb-restricted TB10.44-11, H2-Kd-restricted TB10.420-28, and H-2Kb-
restricted MTB32a309-318-specific CD8 T cells do not recognize and produce IFNg 
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in response to Mtb-infected macrophages. Interestingly, the recognition of g-
irradiated Mtb (“dead bug”) were much lower by ex vivo vaccination-elicited 
TB10.420-28-specific and MTB32a309-318-specific CD8 T cells. This finding could 
present a few issues of some vaccine designs and approaches in using specific 
epitopes for vaccinations. First, Mtb has been shown to modulate its protein 
expression (68, 127, 174), and despite viewing a snapshot from g-irradiated Mtb, 
antigen abundance could restrict the detection. Secondly, the TCRs generated by 
vaccination with synthetic peptides could be specific to the short epitopes rather 
than the bacteria.  
Previous reports have evaluated the ability of CD8 T cells to recognize Mtb-
infected cells including ex vivo murine CD8 T cell recognition of Mtb-infected 
macrophages and DCs (175-177) and human CD8 T cell recognition of Mtb-
infected DCs (178-180). Given the different abilities of macrophages and DCs to 
cross-present to CD8 T cells, the interpretation of results will slightly depend on 
what APCs were used for the infection. Despite lower frequencies than anticipated, 
these studies agreed that CD8 T cells can recognize and respond to infected cells. 
Though antigen specificities have not been identified, we have shown that there is 
a population of polyclonal pulmonary CD8 T cells elicited from Mtb infection that 
recognize infected macrophages (166). However, our data indicate that not all Mtb-
specific CD8 T cells recognize Mtb-infected macrophages. The question of 
recognition of Mtb-infected macrophages by ex vivo polyclonal CD8 T cells is 
addressed in Chapter V. 
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Our results led us to hypothesize that: (1) in contrast to the robust antigen-
specific CD8 T cell responses elicited by Mtb infection in vivo, the low recognition 
ability of these CD8 T cells may be responsible for the disproportionately smaller 
contribution of CD8 T cells to host defense; and, (2) Mtb employs immunodominant 
antigens as a decoy to distract the host from generating potentially protective CD8 
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 EsxH (Rv0288) is an essential gene of Mtb and encodes TB10.4 protein. 
To overcome the attenuation of DesxH strain in assessing immunodomination, we 
used naturally occurring esxH polymorphisms from clinical isolates of Mtb. We 
demonstrated that infection with a clinical isolate expressing polymorphic TB10.4 
protein can cause a drastic shift in the CD8 T cell immunodominant hierarchy in 
C57BL/6 mice. The dominant CD8 T cell response to TB10.44-11 is lost and the 
MTB32a309-318 response becomes dominant. Our data show that 
immunodomination occurs during Mtb infection; immunodominant CD8 T cell 
response toward TB10.44-11 epitope suppresses subdominant CD8 T cell 




Mtb has coexisted with its human host for thousands of years. The 
heterogeneity of both clinical Mtb strains and polymorphic MHC alleles reinforces 
the complexity of host-pathogen interactions, and these interactions could 
influence the immune outcome of infection. Just as Mtb can be clustered into 
lineages that correlate with geographic locations (181), human leukocyte antigens 
(HLA) are also clustered among geographic areas and ethnicities (182). The 
associations between host genetics and Mtb lineages have been identified as 
variables that influence Mtb-human co-adaptation and genetic diversification (104, 
105). 
Recent studies have identified that unlike many other pathogens, which 
undergo genetic mutation as a strategy for immune escape, Mtb genomes are 
highly conserved especially in genes that encode proteins recognized by human T 
cells (110, 111). As Mtb-specific T cell responses are required for protective 
immunity, it is critical to understand the paradox of why Mtb selects to maintain T 
cell responses. One notion suggested that Mtb could benefit from the inflammatory 
environment generated from T cell immunity, which induces disease symptoms 
and ultimately leads to transmission.  
EsxH (Rv0288) is an essential gene of Mtb and encodes the TB10.4 protein. 
TB10.4 is an immunodominant antigen in BALB/c and C57BL/6 mice and 
stimulates T cell responses in people. The TB10.4 protein has a role in 
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mycobacterial iron and zinc acquisition (152) and has recently been shown to 
inhibit class II MHC presentation. Infection with esxH-deficient Mtb strains results 
in greater CD4 T cell activation and CD4-mediated protection (126). In an evolution 
study of Mtb encoded antigenic genes with a small group of clinical Mtb isolates, 
the esxH gene was excluded due to its highly polymorphic nature (110). 
Importantly, we demonstrated that TB10.44-11-specific CD8 T cells do not 
recognize Mtb-infected macrophages nor control bacterial growth (Chapter II, and 
(166)). These findings raise the question of whether Mtb has also adapted to 
diversify its antigenic genes to subvert host immune pressure.  
Given that esxH polymorphisms are prevalent in clinical isolates of Mtb, we 
sought to determine whether host immune responses are affected by 
polymorphisms present in clinical Mtb isolates. In this chapter, we investigate how 
naturally occurring esxH polymorphisms affect immunodominant T cell responses 
and disease outcomes. We hypothesize that polymorphisms in esxH gene could 
alter immunodominant TB10.44-11-specific CD8 T cell responses. Here, we also 
examine the hypothesis that TB10.4 is a decoy antigen as it induces an 
immunodominant CD8 T cell response that distracts the host from recognizing 
other class I MHC epitopes that could mediate protective immunity, and will 




Mycobacterium tuberculosis clinical isolates reveal highly polymorphic 
clusters within the known T cell epitopes of the esxH gene 
To characterize the frequency and type of esxH polymorphisms present in 
clinical Mtb isolates, we analyzed whole-genome sequencing data from a total of 
3,363 isolates from Holt et al. and Walker et al. spanning lineages 1-4 (183, 184). 
We identified a total of 86 isolates containing non-synonymous variants in esxH 
(2.56%), the majority of which (77 isolates) contained mutations between amino 
acids N7 and G13 (Figure 3.1A, Table 3.1).  The fraction of isolates with esxH 
variants in lineage 1 (L1) was strikingly different among other lineages.  75 of 594 
L1 strains analyzed (12.5%) contained esxH polymorphisms, while the rate in L2, 
L3 and L4 were significantly lower with 4 of 1239 (0.32%) for L2, 0 of 529 (0%) for 
L3, and 7 of 1001 (0.7%) for L4 (Figure 3.1A, two-sided chi-square: L1 vs L2, c2 
=147.4, p < 0.0001; L1 vs L3, c2 =71.57, p < 0.0001; L1 vs L4, c2 =108.7, p < 
0.0001).  
To understand the evolution of esxH variants, we constructed whole-
genome single nucleotide polymorphism (SNP)-based phylogenies for each 
lineage separately (Figure 3.1B). We mapped the esxH variations back on the 
phylogeny to calculate the number of times each SNP has evolved independently.  
Within L1, each esxH variant evolved once except for A10V, which evolved 3 times 
and could be found in one clade of four isolates and two unrelated isolates (purple 
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stars, Figure 3.1B). Most esxH variants were relatively rare except P9S and A10T, 
which were found in 17 and 41 isolates, respectively. Given several of the most 
frequent esxH variants within L1 represent related isolates rather than independent 
mutation events, we further calculated whether the acquisition rate of esxH 
variation in L1 was higher than expected based on the acquisition in L2, L3 and 
L4.  By mapping the genome-wide SNP alignment back to the phylogenetic tree, 
we could identify 55,703 SNP mutation events within the L1 phylogeny, of which 
16 were within esxH.  Assuming that each lineage was equally likely to alter esxH 
by chance as any other, the number of variations in L1 was significantly higher 
than expected when compared with L3 (0 of 32400 mutations, two-sided chi-
square, c2 =9.308, p = 0.0023) and L4 (4 of 57937 mutations, two-sided chi-square, 
c2 =7.684, p = 0.0056). The trend was consistent compared with L2 (4 of 36353 
mutations,  c2 =1.783, p = 0.075).  Overall, the data suggest that L1 isolates are 
more likely to acquire esxH polymorphisms compared with the modern L2, L3 and 
L4 strains. The clustering of polymorphisms within reported T cell epitopes 








Figure 3.1: esxH polymorphisms in clinical isolates are highly clustered 
within the known T cell epitopes.  
Whole genome sequencing data were collected from Holt et al. and Walker et al. 
(183, 184). (A) Frequency on the Y axis and type of esxH polymorphisms on the X 
axis were graphed in reference to the polymorphic location on the gene. The color 
of the bars specified the lineages of each clinical isolates: purple for lineage 1 (L1), 
blue for L2, white for L3, and red for L4. The table indicated the number of total 
numbers of polymorphisms in each lineage, and the c2 and p values were 
compared to L1. (B) Whole-genome single nucleotide polymorphism (SNP)-based 
phylogenies represented the polymorphism across all clinical isolates within 
lineage 1. Each circumference line signified different polymorphism noted on top 
in the grey box, and each purple dot cluster represented each time the indicated 
polymorphism evolved independently. Purple stars designated the A10V 
polymorphism which evolved separately 3 times. The table showed the rate of 
esxH variation acquisition by identifying the genome-wide SNP events within each 




Polymorphism Lineage 1 Lineage 2 Lineage 3 Lineage 4 
 Number isolates (Number evolved) 
N7D 2 (1)    
N7S 2 (1)    
P9S 17 (1)    
A10P 1 (1)    
A10T 41 (1)    
A10V 6 (3) 1 (1)  4 (1) 
M11L 1 (1)    
L12F 1 (1)    
G13D 1 (1)    
T24K  1 (1)   
Q57L 1 (1)    
A61V 1 (1)    
H70Y 1 (1) *   1 (1) 
S74R 4 (1) ** 1 (1)   
T75A  1 (1)   
T75S    1 (1) 
H76L 1 (1)    
A89S    1 (1)      
Total 75/594 4/1239 0/529 7/1001 
Percent 12.6% 0.3% 0.0% 0.7%      
 *Also A10V mutant   
 **Also A10T mutants   
 
Table 3.1: Identification of esxH nonsynonymous polymorphisms among 
clinical isolates. The number of times each polymorphism was identified among 
different Mtb lineages is shown, including the number of times each 
polymorphism arose independently.  
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Clinical isolate 667 alters hierarchy of immunodominant antigen-specific 
CD8 T cell responses. 
To determine whether esxH polymorphisms affect immune responses in 
vivo, we used clinical isolate 667. We selected 667 for study because it has a 
single nonsynonymous polymorphism in esxH that results in the A10T amino acid 
substitution, the most frequent variant among the clinical isolates (Figure 3.1A). 
Compared to the well-characterized laboratory reference strain H37Rv, 667 
contains over two thousand SNPs, although there are no polymorphisms among 
the genes encoding other major antigens used to measure T cell responses in the 
mouse M. tuberculosis model (i.e., ESAT6, Ag85B, CFP10, and MTB32a) (185).  
Following Erdman aerosol infection in C57BL/6 mice, 26% of lung CD8 T 
cells were specific for TB10.44-11 while less than 1% were detected after 667 
infection (Figure 3.2A-B). Not only did the frequency of TB10.4-specific CD8 T cells 
differ, but the absolute number of TB10.44-11-specific CD8 T cell was markedly 
lower after 667 infection, a difference which persisted during the course of infection 
(Figure 3.2C, Figure 3.3A). We next determined whether the T cell responses to 
other antigens differed. No differences were detected in the frequency or number 
of ESAT6-specific CD4 T cells elicited by the two bacterial strains (Figure 3.2B-C). 
Interestingly, the frequency and number of MTB32a309-318-specific CD8 T cells was 
significantly greater after 667, increasing from 2% in Erdman to 12% in 667 
infected C57BL/6 lungs (Figure 3.2B-C). The difference in the number of 
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MTB32a309-318-specific CD8 T cells also persisted from 5 to 17 weeks post-infection 
(Figure 3.3B). Independent of the infecting strain, antigen-specific CD8 T cells 
expressed high levels of KLRG1 and low levels of CD127, consistent with a short-
lived effector cell (SLEC) phenotype (Figure 3.3C). Finally, we compared the T cell 
response elicited by 667 and Erdman infection in 96 mice analyzed individually in 
9 independent paired infections. These differences are highly reproducible and 
show that 667 infection elicits a different hierarchy of Mtb-specific CD8 T cells 






Figure 3.2: 667 infection changes the CD8 T cell immunity hierarchy in 
C57BL/6.  
C57BL/6 mice were infected with ~100 aerosolized Erdman or 667 mycobacteria 
and sacrificed at week 5 post-infection. (A) Representative flow cytometry plots of 
H-2Kb/MTB32a309-318 tetramer and H-2Kb/TB10.44-11 tetramer staining of 
pulmonary CD8 T cells following Erdman and 667 infection in C57BL/6 mice. (B) 
Quantification of the percent tetramer staining and (C) the total numbers of 
pulmonary tetramer-specific cells between Erdman and 667 infections. (D, E) 
Compiled comparisons of percentages (D) and total numbers (E) of tetramer 
staining cells in 9 pairs of Erdman and 667 infections. Each point represents the 
average of each tetramer in individual infection, and each line connects the paired 
infections. (A-C) Data is representative of nine experiments. Each experiment 
performed at 4 to 6 weeks post-infection, with 4 to 8 mice per infection. (D, E) 
Compilation of nine experiments and total of 96 mice are shown. n= 48 Erdman-
infected and n=48 667-infected C57BL/6 mice. Statistical testing by a two-tailed, 





Figure 3.3: Alteration of CD8 T cell immunodominant hierarchy persists 
during chronic infection in C57BL/6.  
Total number of (A) TB10.44-11 and (B) MTB32a309-318-specific T cells detected by 
tetramer staining in the lung of infected C57BL/6 mice over the course of infection. 
(C) Proportion of tetramer-specific and tetramer-nonspecific CD8 T cells that were 
KLRG1+ or CD127+. Data is representative of three kinetic experiments. Each 





The effect of variations in the TB10.44-11 epitope on T cell recognition 
We wished to understand why the A10T amino acid exchange in TB10.4 
protein abrogated the CD8 T cell response to the TB10.44-11 epitope. As the 
preponderance of esxH polymorphisms are within the TB10.44-11 epitope, we used 
the Immune Epitope Database tools to predict differences between the abilities of 
the variant epitopes to bind class I MHC (186). Only small differences were 
predicted among the variant epitopes (i.e., P9S, A10T, A10V and M11I) to bind Kb 
compared to the most common sequence (i.e., IMYNYPAM, hereafter referred to 
as “WT”) and all had IC50 values between 5.6 – 9.5 nM (Table 3.2). To 
experimentally confirm these predictions, we performed an RMA-S Kb stabilization 
assay using synthetic WT, P9S, A10T, A10V and M11I peptides (Table 3.3). WT 
peptide stabilized Kb expression as well as the SIINFEKL control (Figure 3.4A). 
Contrary to the prediction algorithm, peptides A10T, M11I, A10V, and P9S were 
all slightly less effective at stabilizing Kb than WT peptide. The non-binding control 
with Y6A/Y8A mutations was designed and predicted to bind Kb 200-fold less well 


















         
WT IMYNYPAMLGHAGDM IMYNYPAM 0.94 0.23 -0.87 1.17 0.30 7.4 
P9S IMYNYSAMLGHAGDM IMYNYSAM 0.82 0.23 -0.75 1.05 0.30 5.6 
A10T IMYNYPTMLGHAGDM IMYNYPTM 1.07 0.23 -0.81 1.30 0.49 6.5 
A10V IMYNYPVMLGHAGDM IMYNYPVM 1.09 0.23 -0.98 1.32 0.35 9.5 
M11I IMYNYPAILGHAGDM IMYNYPAI 1.07 0.33 -0.88 1.40 0.52 7.6 
nonbinder IMANAPAMLGHAGDM IMANAPAM 0.94 0.15 -3.13 1.10 -2.04 1356.5 
 
Table 3.2: IEDB processing analysis: H-2-Kb Processing prediction results 
Predicted processing and binding strength of polymorphic TB10.44-11 epitopes to 
H2-Kb MHC-I by www.iedb.org prediction algorithm (186). Each column indicated 
scores for different processing components and predicted total binding affinity 
(MHC ic50).  
 
The differences in MHC binding among the variant peptides did not seem 
large enough to abrogate T cell recognition. However, alterations of the residues 
that are in contact with the TCR can also affect T cell recognition. To address 
whether the variations in the TB10.44-11 sequence affect T cell recognition, we used 
primary TB10.44-11-specific CD8 T cell lines elicited by Erdman Mtb which has the 
“WT” sequence of the TB10.44-11 epitope (i.e., IMYNYPAM) (Chapter II and (166)). 
The TB10RgR CD8 T cell line recognized and proliferated in a dose dependent 
manner to all polymorphic epitopes with the following hierarchy WT ~ M11I > A10T 
~ A10V > P9S (Figure 3.4B), an order similar to their ability to stabilize cell surface 
67 
 
expression of Kb on RMA-S cells. Thus, we infer that peptide binding to Kb was 
largely driving T cell recognition.  
We used additional TB10.44-11-specific CD8 T cell lines (TB10Rg3, 
TB10RgL and TB10RgP) with distinct TCRs and compared their abilities to 
recognize the WT and A10T epitopes. All four T cell lines recognized the two TB10 
epitopes with a similar hierarchy: TB10RgP ~ TB10Rg3 > TB10RgR > TB10RgL 
(Figure 3.4C). While TB10RgP, TB10Rg3, and TB10RgR all recognized the WT 
and A10T epitopes similarly, TB10RgL only recognized the A10T epitope with low 
avidity (Figure 3.4D). Importantly, the TCRs used by TB10RgR and TB10RgL only 
differ by two amino acids – one in the CDR3a region and one in the CDR3b region 
(Figure 2.1A). As both of these T cells were elicited by the WT epitope, and were 
clonally expanded in vivo (161), these data show the fine specificity of TCRs for 
their cognate antigens, and reveals how T cells elicited against one Mtb strain 
(including vaccine strains) may be unable to recognize other Mtb strains. 
Importantly, these data also show A10T epitope of 667 can both bind to Kb and be 
recognized by T cells. Thus, CD8 T cells should have the capacity to recognize 
and respond to epitopes with the EsxHA10T polymorphism in 667 infection. The 
absence of an effective TB10.44-11-specific CD8 T cells response following 667 
infection could exemplify the use of escape mutation or dysfunctional APC as 












1 of 21  MSQIMYNYPAMLGHA 
2 of 21      MYNYPAMLGHAGDMA 
3 of 21          PAMLGHAGDMAGYAG 
4 of 21              GHAGDMAGYAGTLQS 
5 of 21                  DMAGYAGTLQSLGAE 
6 of 21                      YAGTLQSLGAEIAVE 
7 of 21                              LQSLGAEIAVEQAAL 
8 of 21     GAEIAVEQAALQSAW 
9 of 21         AVEQAALQSAWQGDT 
10 of 21             AALQSAWQGDTGITY 
11 of 21                 SAWQGDTGITYQAWQ 
12 of 21                     GDTGITYQAWQAQWN 
13 of 21                         ITYQAWQAQWNQAME 
14 of 21                             AWQAQWNQAMEDLVR 
15 of 21        QWNQAMEDLVRAYHA 
16 of 21            AMEDLVRAYHAMSST 
17 of 21                LVRAYHAMSSTHEAN 
18 of 21                    YHAMSSTHEANTMAM 
19 of 21                        SSTHEANTMAMMARD 
20 of 21                            EANTMAMMARDTAEA 
21 of 21                                MAMMARDTAEAAKWGG 
MTB32a 309-318 GAPINSATAM 
ESAT6 1-15 MTEQQWNFAGIEAAA 
TB10.4 20-28 GYAGTLQSL 
TB10.4 74-88 STHEANTMAMMARDT 
EspA 150-158 AYLVVKTLI 
 
Table 3.3: Sequences of peptide used in this study. 
TB10, A10T, A10V, P9S, M11I, non-binder and positive peptides were used in 
RMA-S and T cell proliferation assays. The 21-peptide array containing 15- or 
16-mers overlapping 11-mer spanning the TB10.4 protein were obtained from 





Figure 3.4: TB10.44-11 epitope variants bind and stimulate T cell recognition.  
(A) RMA-S H-2Kb stabilization assay with titrated concentrations of positive control 
peptide SIINFEKL (brown), WT TB10.44-11 (blue), A10T (red), A10V (green), P9S 
(orange), M11I (purple), and negative control IMANAPAM (black). H-2Kb surface 
expressions were presented by the median of fluorescent intensity from antibody 
staining and flow cytometry. (B) IMYNYPAM-specific TB10RgR T cell proliferation 
assay was measured by eFlour450 proliferation dye dilution at 48 hours post-
stimulation with thioglycolate-elicited peritoneal macrophages pulsed with 
indicated polymorphic peptides at titrated concentrations. (C, D) TB10RgP, 
TB10Rg3, TB10RgR, and TB10RgL CD8 T cell lines with different TCR and avidity 
were used in the T cell proliferation assays described above with WT TB10 peptide 
(C) or A10T peptide (D). Data is representative of four experiments. 
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H-2Kb/TB10.44-11A10T tetramer verifies the loss of TB10.44-11-specific CD8 T 
cells 
Although CD8 T cells elicited by Erdman recognized the polymorphic 
EsxHA10T epitope, we considered the possibility that CD8 T cells elicited by 667 
might not recognize the WT epitope. In other words, could the loss of the TB10.44-
11-specific CD8 response following 667 infection arise because of a failure of the 
Kb/IMYNYPAM tetramers to bind TCRs specific for IMYNYPTM? To evaluate this 
possibility, we used H-2Kb/TB10.44-11WT tetramer (i.e., loaded with the IMYNYPAM 
epitope) as well as tetramers loaded with the H-2Kb/TB10.44-11A10T epitope (i.e., 
IMYNYPTM). Following 667 infection, dual tetramer staining showed that CD8 T 
cells elicited by Erdman infection bound preferentially to H-2Kb/IMYNYPAM 
tetramers while 667 infection elicited TB10.4-specific CD8 T cells were only 
detected using H-2Kb/IMYNYPTM tetramers (Figure 3.5A). When staining the 
tetramers independently, H-2Kb/IMYNYPTM tetramers detected more TB10.4-
specific CD8 T cells than the H-2Kb/IMYNYPAM tetramers in 667-infected animals, 
although the number of events was only incrementally greater (Figure 3.5B). Thus, 
there is a significant reduction of TB10.44-11-specific CD8 T cells after 667 infection.  
We further sought to confirm the specificity of tetramers to the antigen-
specific cells following 667 and Erdman infection. To assess, we performed titrated 
H-2Kb/TB10.44-11WT and H-2Kb/TB10.44-11A10T tetramer staining on Mtb infection-
elicited pulmonary cells. We observed highly specific CD8 T cells elicited from 
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Erdman infection to H-2Kb/IMYNYPAM tetramer, both frequency and mean 
fluorescent intensity (MFI) (Figure 3.5C, D, E). The H-2Kb/IMYNYPAM tetramer 
detected a lower frequency of cells from 667 infection, which also had a lower MFI 
and a lower avidity based on the tetramer-binding dose response (Figure 3.5E). 
Similarly, the H-2Kb/IMYNYPTM tetramer did not bind as well to the Erdman-
elicited CD8 T cells (Figure 3.5C, D, F). 667-elicited CD8 T cells, on the other hand, 
were detected at higher frequencies and higher MFI when stained with H-
2Kb/IMYNYPTM tetramer, indicating the superior specificity (Figure 3.5C, D, F). 
Lastly, the detection of H-2Kb/MTB32a tetramer was not affected by the presence 
of either H-2Kb/TB10.44-11 tetramers (Figure 3.5 E, F). Together, this result 
depicted the preferential specificity of Erdman-elicited CD8 T cells to H-













Figure 3.5: H-2Kb/TB10.44-11A10T tetramer verifies the loss of TB10.44-11-
specific CD8 T cells 
(A) Representative flow cytometry plot of H-2Kb/TB10.44-11WT and H-2Kb/TB10.44-
11A10T dual tetramer staining of CD8 T cells from the lungs of Erdman- or 667- 
infected C67BL/6 mice. (B) Total numbers of pulmonary TB10.4-specific CD8 T 
cells determined by staining with H-2Kb/TB10.44-11WT or H-2Kb/TB10.44-11A10T 
tetramers. Each point represents an individual infected mouse from Erdman (filled 
circle) or 667 (empty circle) infections. n=40 mice from 8 independent infections. 
(C-F) H-2Kb/IMYNYPAM or H-2Kb/IMYNYPTM tetramers, together with H-
2Kb/MTB32a309-318 tetramer, were serially diluted from 1:100 to 1:25600 to detect 
antigen-specific cells following Erdman and 667 infections. Cells were gated on 
CD8 T cell populations. (C) Percentages and (D) mean fluorescent intensity (MFI) 
of the Erdman-elicited (filled) and 667-elicited (empty) CD8 T cells were graphed 
for positive H-2Kb/IMYNYPAM (black) or H-2Kb/IMYNYPTM (red) tetramer staining 
at different tetramer concentrations. (E-F) Representative flow cytometry plots of 




The H2-Kd-restricted TB10.420-28-specific CD8 T cell response is unchanged 
after 667 infection 
Mtb infection of BALB/c mice elicits H-2Kd-restricted CD8 T cells specific for 
TB10.420-28 and I-Ad-restricted CD4 T cells specific for TB10.474-88 epitope (157, 
158). Although the EsxHA10T polymorphism is located outside of the TB10.420-28 
and TB10.474-88 epitopes, we sought to determine whether the EsxHA10T 
polymorphism affected these T cell responses. Erdman- or 667-infected BALB/c 
mice were found to generate similar frequencies and numbers of both TB10.474-88-
specific CD4 T cell and TB10.420-28-specific CD8 T cell responses (Figure 3.6 A-
C). This result suggested that TB10.4 proteins were expressed at similar amounts 
in 667 bacteria compared to Erdman bacteria during in vivo infections. To examine 
an independent epitope recognized by CD8 T cells, we quantified the response to 
the EspA150-158 epitope (157). Both 667 and Erdman elicited similar frequencies of 
EspA150-158-specific CD8 T cells in the lungs of infected mice (Figure 3.6 A-C).  The 
similar CD8 T cell responses following 667 or Erdman infection in BALB/c mice, in 
contrast to the shift in the CD8 T cell hierarchy observed in C57BL/6 mice, 







Figure 3.6: 667 infection elicited similar CD8 T cell immunity in BALB/c.  
BALB/c mice were infected with ~100 aerosolized Erdman or 667 Mtb and 
sacrificed at week 5 post-infection. T cell responses were analyzed by tetramer 
staining and flow cytometry. (A) Representative flow cytometry plot of I-
Ad/TB10.474-88-specific CD4 T cells (top) and H-2Kd/TB10.420-28 or H-2Kd/EspA150-
158-specific CD8 T cells (bottom) following Erdman and 667 infection in BALB/c 
mice. (B) Percentages and (C) total cell numbers of tetramer specific cells from 30 
mice from 3 independent timepoints of Erdman (dark purple, dark green, black) or 
667 (light purple, light green, grey) infections were graphed. Statistical testing by 






No cryptic epitope emerged in the absence of immunodominant epitope 
When the immunodominant epitope of ESAT61-20 was ablated, new sub-
dominant T cell responses to cryptic epitopes of ESAT6 emerged (187). 
Accordingly, we hypothesized that a loss of the TB10.44-11-specific CD8 T cell 
responses may lead to the emergence of new TB10.4 epitopes recognized by CD8 
T cells following 667 infection in C57BL/6 mice. We used a TB10.4 peptide library 
consisting of 15mers overlapping by 11 amino acids, supplemented with known 
peptides corresponding to known epitopes (Table 3.3). These were used to screen 
the pulmonary and splenic T cells elicited by 667 infection, to identify any possible 
novel CD8 T cell responses.  Consistent with the flow cytometry data using 
tetramers, we did not detect IFNg production in response to the immunodominant 
TB10.44-11 epitope in 667 infection, while the MTB32a309-318 sub-dominant epitope 
response increased in magnitude (Figure 3.7A). However, no new epitopes from 
TB10.4 were identified. When screening the peptide library using T cells obtained 
from the lungs of infected BALB/c mice, we detected IFNg production that was 
proportional to the frequencies of antigen-specific T cells based on tetramer 
staining: similar levels of TB10.474-88 and slightly decreased TB10.420-28 responses 
in 667-infected samples (Figure 3.7B). To control for possible genetic variations in 
antigen presentation between BALB/c and C57BL/6 mice, we infected CB6F1 
(C57BL/6 x BALB/c F1) mice, and only responses to the known H2b- and H2d-
restricted epitopes were detected (Figure 3.7C). Therefore, unlike ESAT6, no 






Figure 3.7: No cryptic epitope in the absence of immunodominant epitope.  
Single-cell suspensions from the lungs of Erdman- or 667-infected (A) C57BL/6 
(B) BALB/c or (C) CB6F1 mice were isolated and incubated with a TB10.4 peptide 
library (21 peptides of 15mers overlapping by 11 amino acids) and the indicated 
control peptides. Supernatants were collected at 48 hours post-stimulation and 
IFNg secretion was detected by ELISA. Data is representative of at least two 





667 infection induces less severe disease outcomes 
To assess whether the altered CD8 T cell response affected the virulence 
of the two bacterial strains, we compared the ability of Erdman and 667 to cause 
disease in C57BL/6 mice after low-dose infection by the aerosol route. Across 13 
independent experiments, 667-infected mice had fewer bacteria in their lungs and 
spleens compared to Erdman-infected mice (Figure 3.8A-B). In two independent 
experiments, 667-infected mice had prolonged survival compared to Erdman-
infected mice, suggesting that 667 is less virulent than Erdman (Figure 3.8C). The 
ability of mice to resist mycobacterial infection is ultimately determined by both 
innate and elicited immunity.  However, the intrinsic virulence of the bacterial strain 
could also play a role. For example, while 667 is a clinical isolate, and therefore by 
definition is a pathogenic strain, Erdman has been passaged through mice to 
maintain its virulence in the mouse model.  
To address this question, C57BL/6 and RAG1 KO mice were infected with 
a pool of barcoded Mtb clinical isolates, which also contained Erdman and H37Rv, 
by intravenous route. In the absence of pressure from the adaptive immune 
response, 667 grew more (ie. fold change from day 1 to week 2 or week 3 post-
infection) than Erdman in the spleens of RAG1 KO mice (Figure 3.8D). Both 
Erdman and 667 strains were similarly controlled by adaptive immunity, as 
indicated by the similar increase in the relative proportion of the strains between 2 
to 3 weeks in the spleens of C57BL/6 mice. The situation differed in the lung; 
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Erdman had greater overall fitness in the lung, although the relative increase 
between week 2 to week 3 post-infection in RAG1 KO was similar for both Erdman 
and 667 (Figure 3.8E), indicating that 667 increased in abundance between week 
2 and week 3 post-infection in C57BL/6 mice. Together, these data show that 
based on its fitness in immunodeficient mice and its ability to compete in the 
spleen, 667 is not intrinsically attenuated. However, the reduced fitness of 667 in 
the lung, compared to Erdman, is consistent with the prolonged survival of mice 













Figure 3.8: Infection with 667 is less virulent than Erdman.  
The bacterial burden as measured by CFU from lung (A) or spleen (B) 
homogenates from Erdman (filled) or 667 (open) infected C57BL/6 at different 
timepoints post-infection. CFU data were compiled from 13 (lung) or 6 (spleen) 
independent experiments, from 4 to 30 weeks post-infection. (C) The survival of 
C57BL/6 mice after Erdman (solid) or 667 (dashed) infection, which is one of two 
independent experiments with similar results. In this experiment, the d1 CFU was 
158 (667) or 55 (Erdman). (D-E) A barcoded pool of clinical isolates was 
administered intravenously to C57BL/6 or RAG1 KO mice, and 5 mice of each 
strain were harvested, CFU recovered 1, 14, and 21 days post-infection. The 
relative abundance of the different Mtb strains in the (D) spleen or (E) lung was 






Specific clinical isolates of Mycobacterium tuberculosis have been shown 
to induce different immune responses, resulting in differential pathogenicity and 
disease outcomes (189-191). Clinical isolate CDC1551 was identified by a 
remarkably high rate of TST conversions during an Mtb outbreak but resulted in a 
low number of active TB cases. It was subsequently shown that CDC1551 elicited 
earlier and more vigorous Th1 cytokine response in the lung of infected mice 
compared to Erdman and H37Rv lab strains (190, 192). In contrast, HN878 was 
associated with a strikingly high proportion of active TB and extrapulmonary 
disease cases (192); it was later determined that HN878 infection failed to produce 
an effective Th1 immune response (189). These findings indicate that genetic 
diversity of Mtb impacts immunological responses and leads to differential disease 
outcomes (189-191). They also raise the question of what type of immune 
responses are generated in individuals infected with mixed variant Mtb strains 
(193). In addition, phenotypical antigen-specific T cell responses have never been 
examined following infection with Mtb strains bearing polymorphisms in the genes 
encoding antigens.  
As most of Mtb-encoded T cell epitopes are more conserved than its 
essential genes, the lack of antigen-specific T cell studies is partly due to the low 
sequence variability (110). Comas et al. speculated that some detection of Mtb-
infected cells by host immunity might be beneficial for the mycobacteria to 
establish a latent infection in the granulomas or contribute to transmission (110). 
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The conservations were confirmed with the unbiased computational study, with the 
exception of a handful of genes including esxH (111). Here, in addition to the 
previous study showing that esxH is highly polymorphic, we further reveal the 
naturally occurring polymorphic hotspots within previously reported human CD8 T 
cell epitopes of esxH genes that are highly prevalent in lineage 1 of Mtb. The high 
frequency of amino acid substitutions in TB10.4 in the Indian Ocean of lineage 1 
further suggests the co-adaptation with a subset of human leukocyte antigens and 
ongoing immune evasion. 
We determined that the A10T single amino acid exchange in TB10.44-11 
epitope in clinical isolate 667 resulted in the frequency of TB10.44-11-specific CD8 
T cell responses falling from ~30% (after infection with Erdman or H37Rv) to 1%, 
possibly reflecting the interference either with antigen presentation or T cell 
recognition. This is surprising because TB10.44-11-specific CD8 T cells can 
recognize the polymorphic TB10.44-11 epitopes similarly, and the small reduction 
in the recognition sensitivity cannot justify for the 30% CD8 T cell loss. In addition, 
the use of H-2Kb/TB10.44-11A10T helped identified a different TCR repertoire of 
antigen-specific CD8 T cells in 667 infected mice. This alteration of TCRs in 
polymorphic epitopes has previously been reported in SIV infections (194) as well 
as influenza (195).  
The Maurer group assessed human CD8 T cell specificity to TB10.44-11A10T 
by generating human multimers with common MHC allotypes in a South African 
population. The researchers inferred in their study that most of the esxH 
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polymorphic substitutions decreased the binding to human class I MHC and, 
hence, the peptide presentation. However, both the nature of class I MHC 
molecule and amino acid composition of the epitope determine the affinity of 
binding affect the priming and outcome of antigen presentation. Human HLAs used 
in this study are different from H-2Kb in C57BL/6 mice. In addition, while the 
researchers detected a small population of TB10.44-11A10T-specific CD8 T cells in 
PBMC from Mtb-infected patients (154), the study did not identify the bacterial 
strains that subjects were infected with. The undetermined genotypes of Mtb 
preclude the understanding of whether the multimer-detected CD8 T cells were 
generated by the TB10.44-11A10T epitope or were instead cross-reactive from the 
WT epitope.  
Interestingly, the typical subdominant response to MTB32a309-318 in 
Erdman-infected C57BL/6 mice became more dominant during 667 infection. This 
phenomenon of TB10.44-11 immunodominating MTB32a309-318 was strikingly similar 
to cowpox viruses (CPXV) where the deletion of the immunodominant epitope from 
CPXV gave rise to a compensation and domination by subdominant epitopes 
(137). In the other words, this finding implies that TB10.44-11 may inhibit 
MTB32a309-318 from inducing antigen-specific CD8 T cell response.  
Mice infected with 667 exhibit prolonged survival compared to Erdman-
infected mice. During the competitive Mtb pool infection, 667 grows intrinsically 
slower from day 1 to day 14 post-infection (prior to the initiation of adaptive 
immunity) compared to Erdman and H37Rv. However, in immunodeficient mice, 
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the results suggest that 667 is as virulent as Erdman, if not more. Nevertheless, 
bacterial burdens in the lungs and spleens of 667-infected C57BL/6 are equal or 
lower than Erdman-infected mice. Together, 667 appears to be subject to 
clearance by immune responses more efficiently than Erdman Mtb. 
This chapter shows that naturally occurring polymorphisms can have drastic 
effects on host immune responses and is evidence that Mtb could employ 
immunodomination over subdominant CD8 T cell responses as an evasion 
strategy. Since TB patients are prone to re-infection (196) and most people in 
developing countries are BCG-vaccinated, pre-existing immune responses and the 
genetic diversity of Mtb could impact the outcome of subsequent Mtb infections. A 
better understanding of T cell immune response to clinical isolates of Mtb will be 
of value in determining the nature of clinically relevant responses, which in turn 




CHAPTER IV. THE EFFECTS OF A10T AMINO ACID SUBSTITUTION 
OF MYCOBACTERIUM TUBERCULOSIS ESXH PROTEIN ON HOST 
CD8 T CELL RESPONSES 
 
Rujapak Sutiwisesak1, Shayla Boyce1, Kadamba Pavinasasundaram1,  
Kenan C. Murphy1, Christopher Sassetti1, Samuel Behar1 
1Department of Microbiology and Physiological Systems, University of 
Massachusetts Medical School, Worcester, Massachusetts USA 
 
Parts of this chapter were included in the manuscript in preparation: 
Sutiwisesak R, …, Behar SM. “A natural polymorphism of Mycobacterium 
tuberculosis in the EsxH gene disrupts immunodomination by the TB10.4-specific 
CD8 T cell response” 
 
Attributions:  
K.M., K.P. and C.S. provided guidance in strategies to use for the generation of 
isogenic ErdWT and ErdA10T Mtb. K.M. and K.P. designed and assisted in 
generating isogenic ErdWT and ErdA10T Mtb in Figure 4.1. Shayla B. provided 
assistance in performing experiments in Figure 4.2 and 4.3. R.S. and S.B designed 
all other experiments. R.S. performed all experiments and statistical analysis. S.B. 




 To verify that the change in antigen specificity was not influenced by other 
genetic polymorphisms in the Mtb clinical isolate, we generated Mtb isogenic 
strains expressing either EsxHWT or EsxHA10T. Given the essentiality of esxH, the 
genetic engineering process was achieved by oligo-mediated recombineering to 
bypass the creation of a genetic deletion strain. Using the isogenic strains, I 
confirmed that A10T amino acid substitution in TB10.4 caused the drastic shift in 
immunodominant hierarchy of CD8 T cell responses. The results from infections 
with isogenic strains validate the immunodomination phenomenon during Mtb 
infection that could impact the frequency of CD8 T cells that can recognize and 





Chapter III results showed that naturally occurring polymorphisms between 
pathogenic human isolates of Mtb strains can alter the hierarchy of antigens that 
CD8 T cells recognize and can affect the outcome of infection. However, there are 
over two thousand single nucleotide polymorphisms (SNPs) in the Erdman 
chromosome compared to 667, any of which could affect these processes. To 
demonstrate that the A10T amino acid substitution of EsxH protein in 667 Mtb is 
responsible for the altered CD8 T cell response generated by infection, we need 
precisely altered bacterial strains. Below describes a brief introduction to 
approaches in Mycobacterium tuberculosis genetic engineering. 
The precise modification of Mtb genomes has been central for defining the 
important functions in physiology and pathogenicity of this important pathogen. 
Previous methods of genetic modification in Mtb have relied on bacterial 
endogenous recombination systems for the insertion of an inactivated copy of a 
target gene into the bacterial chromosome using non-replicating vectors (197-
199). These methods, however, generated a rare number of desired recombinants 
because of (1) the low frequencies of plasmids spontaneously integrating into 
bacterial chromosomes, (2) the inefficient uptake of DNA by electroporation, and 
(3) illegitimate recombination events, a long-standing problem for mycobacterial 
gene replacement methods (although useful for random mutagenesis schemes 
(200, 201). In addition, once the inactivated copy of the target gene was transferred 
to the chromosome, resolution of the co-integrant required a second crossover 
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event to complete formation of the allelic exchange recombinant. Since this event 
occurred at a much lower efficiency, counter-selection approaches such as using 
the sucrose sensitive marker sacB were adopted (199, 202, 203). The efficiency of 
the approach has been greatly improved by the use of a specialized transduction 
scheme, which uses phage to deliver recombination substrates to nearly every cell 
(204). This method, however, is time-consuming and demands numerous 
technical steps. 
Though these approaches were instrumental in developing gene transfer 
systems for Mtb, the isogenic EsxHA10T- and EsxHWT-expressing Erdman strains 
described below were established by oligo-mediated recombineering (for 
recombinogenic engineering). Recombineering was first introduced in Escherichia 
coli (E. coli) (205, 206) and developed for use in mycobacteria over the last decade 
to enhance the accuracy and efficiency of genetic modification (207-209). 
Recombineering in E. coli utilizes the phage lambda Red recombination system 
for linear double-stranded DNA transformation, while oligo-mediated 
recombineering requires only expression of the Che9 mycobacteriophage RecT 
annealase (the lambda Beta protein) to facilitate annealing of SNP-containing 
oligos to the Mtb DNA replication fork and subsequent integration.  
SNPs transferred to Mtb in this fashion allow us to test if the EsxHA10T, in an 
otherwise identical genetic background, recapitulates the phenotypical change 
observed in the original clinical isolate 667. Therefore, we genetically engineered 
isogenic strains that differed only at codon 10 in the EsxH protein to test the 
92 
 
following hypothesis: the A10T amino acid replacement in esxH gene is 
responsible for the shift in CD8 T cell immunodominance. Since EsxH protein has 
been described as a virulence factor and its gene knockout led to an attenuation 
in vivo (152), we also assessed whether the esxHA10T allele affects the virulence 





Generation of Isogenic EsxHWT and EsxHA10T in Erdman Mtb 
To demonstrate that the EsxHA10T polymorphism is responsible for the 
altered CD8 T cell response elicited by Mtb, we generated isogenic Erdman strains 
containing EsxH protein with A10T substitution by oligo recombineering as 
previously described (207-210) (Figure 4.1A).  
The transfer of the original naturally occurring SNP in the clinical isolate 667 
strain, to the Erdman strain (which has the “WT” sequence) required the use of an 
oligo that would create a G/T mismatch at the target site in the replication fork. This 
mismatch was anticipated to be repaired by the mismatch repair (MMR) system of 
mycobacteria (K. Murphy, unpublished observations), creating the inefficiency in 
SNP transfer. To increase the frequency of SNP transfer, we designed a 144 
basepair (bp) oligo to create a mismatched “bubble” where 3 out 4 bps of codon 
10 and the wobble position of codon 9 were mismatched, yet still encoded only an 
alanine to threonine substitution in codon 10 in the TB10.4 protein. This design 
was based on observations from E. coli recombineering where multiple 
mismatches in a row caused local strand unpairing and caused the 4bp region to 
become unrecognizable to MMR (211). Below is the 144bp oligo in reverse 






TCGGTCAGCAGGGTTCGATCAGAACCCGGTAT 3’   
The EsxHA10T-conferring oligo was delivered together with an oligo 
encoding a K43R mutation in the RpsL protein, which confers resistance to 
streptomycin for selection. As such, streptomycin-resistant colonies are indicative 
of DNA uptake and successful recombinogenic events, increasing the probability 
of finding a strain obtaining the EsxHA10T modification.  Candidate colonies were 
screened for the A10T exchange by targeted PCR analysis, which was made 
possible by using the “bubble” sequences in the 3’ end of the primers (see Figure 
4.6 in discussion below). The selected colonies were then confirmed by Sanger 
sequencing.  
esxHA10T forward primer 5’ TCATGTACAACTACCCGACC 3’ 
esxHWT forward primer 5’ TCATGTACAACTACCCCGCG 3’ 
 
The genetic alteration resulted in a single amino acid change in the 
TB10.44-11, changing the epitope from IMYNYPAM (i.e., the Erdman epitope) to 
IMYNYPTM (the 667 epitope). Hereafter, we refer to these isogenic strains as 
ErdWT and ErdA10T, respectively. The isogenic strains had equivalent expression 
of transcripts of the genes that encode immunodominant antigens, including 








Figure 4.1: Generation of EsxHA10T and EsxHWT isogenic strains.  
(A) Schematic representation of oligo recombineering method to generate isogenic 
strains, previously described in (210). (B) Relative expression of Mtb (from left to 
right) Rv0287, Rv0288, Rv0125, Rv3875, Rv3874, Rv1886c and Rv3019c mRNAs 
in broth culture. Copy numbers of indicated mRNAs were determined by RT-PCR 
and normalized to constitutively expressed 16S rRNA. (See Materials and Method 







Isogenic ErdWT and ErdA10T Mtb stimulate different CD8 T cell immunity in 
C57BL/6 
We determined the antigen-specific T cell responses after infection with the 
isogenic strains ErdWT and ErdA10T. The TB10.44-11-specific CD8 T cell response 
was significantly reduced while the MTB32a309-318-specific CD8 T cell response 
was significantly increased after infection with ErdA10T compared to ErdWT in 
C57BL/6 mice (Figure 4.2A, B). The magnitude of the CD4 T cell response to 
ESAT6, Ag85B, and EsxG, elicited by ErdWT and ErdA10T were similar and 
recapitulated the CD8-specific differences elicited by Erdman versus 667. In 
addition, similar to what we observed after Erdman and 667 infection, the Mtb-
specific CD4 and CD8 T cell responses after ErdWT or ErdA10T did not differ in 
BALB/c mice (Figure 4.3).  
To confirm these results, we compared the antigen-specific T cell responses 
elicited by ErdWT and ErdA10T in 5 independent paired infections containing a total 
of 50 C57BL/6 mice. The differences are highly reproducible and show that the 
EsxHA10T polymorphism in the 667 Mtb strain causes a shift in the hierarchy of CD8 
T cell responses observed after infection of C57BL/6 mice (Figure 4.2C, D). Thus, 
immunodomination by the TB10.44-11 epitope may inhibit the magnitude of the CD8 
response to the MTB32a309-318 epitope, and prevent it from being a more significant 








Figure 4.2: Infections with isogenic ErdWT and ErdA10T Mtb validate the 
immunodominant shift of CD8 T cell hierarchy in C57BL/6 mice.  
C57Bl/6 mice were infected by the aerosol route with ~100 ErdA10T or ErdWT Mtb 
and the lung mononuclear cells were analyzed 5 weeks after infection (A) 
Representative flow cytometry plots of; (top) MTB32a309-318 tetramer and TB10.44-
11 tetramer binding CD8 T cells; (middle) ESAT6 tetramer binding CD4 T cells; and 
(C) Ag85B tetramer and EsxG tetramer binding CD4 T cells. (B) Quantification of 
the frequency of tetramer+ T cells (top) and the total tetramer-specific T cell 
numbers (bottom) elicited by infection with the isogenic ErdA10T and ErdWT Mtb 
strains. Compiled comparisons of (C) percentages and (D) total numbers of 
tetramer staining cells in 5 pairs of ErdA10T or ErdWT infections. Each point 
represents the average frequency or number of tetramer+ cells of individual mice, 
and the lines connect paired infections. (A-B) Data is representative of five 
experiments. Each experiment performed at 5 to 6 weeks post-infection, with 5 
mice per group. (C-D) Compile of five experiments and total of 50 mice is shown. 
Statistical testing by a two-tailed, unpaired Student’s T test. *, p<0.05; **, p<0.01; 















Figure 4.3: A10T substitution of TB10.4 protein does not change the amount 
of antigen-specific CD4 and CD8 T cell numbers in BALB/c mice.  
(A) Representative flow cytometry plots of (top) CD8 T cells specific for H-
2Kd/TB10.420-28 and H-2Kd/EspA150-158 tetramers and (bottom) CD4 T cells specific 
for I-Ad/TB10.474-88 and I-Ad/Ag85A tetramers at 5 weeks post-infection. 
Quantification of the (B) frequencies and the (C) numbers of antigen-specific CD4 
and CD8 T cell responses determined by tetramer staining after infection with the 
isogenic ErdA10T and ErdWT Mtb strains in BALB/c. Data is representative of two 
experiments. Each experiment performed at 5 weeks post-infection, with n=5 mice 
per group. Statistical testing by a two-tailed, unpaired Student’s T test.  
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A10T substitution of TB10.4 protein does not affect virulence and bacterial 
burden  
Despite the change in immunodominant antigen-specific CD8 T cell 
responses, we did not observe differences in pulmonary or splenic bacterial loads 
after infection with isogenic ErdA10T or ErdWT Mtb strains (Figure 4.4). This result 
indicated that the EsxHA10T variant did not affect the virulence of the isogenic 
bacterium. 
 
Figure 4.4: Isogenic strain infection does not impact bacterial burden.  
Comparisons of pulmonary (left) and splenic (right) colony forming units (CFU) 
from seven pairs of infections performed with ErdA10T (red) or ErdWT (blue) isogenic 
Mtb strains. A total of 70 mice were analyzed at 5-, 6- or 19-weeks post-infection 
as indicated. Each data point represents the bacterial burden from an individual 
mouse. The different experiments are identified by unique symbols (circle, upward 
triangle, downward triangle, square, or diamond), and matched symbols at 5- and 
19-weeks post-infection indicate the group of mice from the same corresponding 




To our knowledge, this is the first demonstration of a single amino acid 
substitution causing a major antigenic shift in the Mtb-specific CD8 T cell response 
following infection with virulent Mtb. These results support the hypothesis that 
immunodomination (as discussed in Chapter III) contributes to the dominance of 
the CD8 response to TB10.4. These results also give further credence to the 
importance of pre-existing immunity as a factor to consider when developing 
vaccination strategies for the prevention of Mtb infections, particularly in individuals 
vaccinated with BCG or exposed to environmental mycobacteria.  
The validation of the immunological outcomes observed after infection with 
the clinical isolate 667 required the generation of isogenic ErdWT and ErdA10T 
strains. This was more challenging than originally anticipated. The esxH gene is a 
part of the esx3 operon, which is an essential and a large operon, spanning 11 
genes and is almost 15 kB long (152). We used four different strategies to replace 
the endogenous esxH gene with one containing the EsxHA10T modification.  
(1) In the first scheme, I received a DesxG-esxH knockout H37Rv from Dr. 
William Jacobs (152), which was marked with a drug-resistant cassette containing 
the sucrose counter-selection gene, sacB. I used dsDNA recombineering to 
replace this cassette with the esxH gene bearing either the EsxHWT or EsxHA10T 
alleles, flanked by 500 bp of target homology DNA, and selected for sucrose 
resistance.  However, the gene knockout cassette obtained from the Jacobs lab 
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contained gd-resolvase flanking sites, which are typically used to create unmarked 
gene knockouts. The gene replacement attempts failed, however, because the 
recombination event between my linear dsDNA substrates and the chromosome 
was far less efficient than the spontaneous recombination event between the two 
chromosomally located gd-resolvase sites. This resulted in the excision of the drug 
resistance marker without the incorporation of the desired DNA and generation of 
sucrose-resistant colonies. It is unclear if expression of the Che9c RecET proteins 
had an effect on the rate of spontaneous recombination between the  gd-resolvase 
sites. 
(2) Next, I used the ORBIT technique, a Che9 RecT-promoted oligo 
recombineering system that employs an attP site within the oligo, a co-
electroporated attB-containing non-replicating plasmid, and the expression of 
Bxb1 phage Integrase.  This system promotes the integration of attP into the target 
site, followed by integration of the plasmid containing a selectable marker at the 
nascent attP site (210). I attempted the construction of (a) an A10T substitution in 
esxH and (b) knockouts of esxH (Rv0288), esxG-esxH (Rv0287-88), and esxG-
esxH-espG3 (Rv0287-89). However, even with the iron supplementation to 
overcome the iron acquisition function of EsxH, we were not able to recover any 
candidates. We speculated that the disruption of separate parts of this operon was 




(3) Since we received the DesxG-esxH strain, we generated 
complementation strains with an L5-integration plasmid expressing EsxG-EsxHWT 
or EsxG-EsxHA10T from the groEL promoter. However, I discovered that despite the 
normal growth in liquid and agar culture, the groEL complemented strains failed to 
grow during in vitro infections and in vivo aerosol infections. We later received the 
DesxH KO strain and DesxH::esxG-esxHWT-espG3 complementation strain from 
Dr. Jennifer Philips. The complementation plasmid contained the hsp60 promoter, 
a homolog to groEL promoter, but with two additional adjacent genes flanking esxH 
in the integration plasmid construct. Through personal communications, we 
learned that the expression level of esxH is critical for mycobacterial virulence; too 
weak or too strong of expression would result in an attenuation. This could be 
partly explained by the operon structure, where there are only one or two 
promoters, and genes expressed later in the operon are likely expressed at lower 
levels. We later constructed the DesxH::esxG-esxHA10T-espG3 complementation 
strain using hsp60 promoter. The hsp60-complemented strains were able to grow 
during both in vitro infections and in vivo aerosol infections. However, the 
pulmonary bacterial burdens at the peak of infection (4 weeks post-infection) were 
over 10-fold lower than Erdman and 667 strains (Figure 4.5). The different amounts 
of bacteria in the lung affected how much T cell immunity was elicited. Therefore, 





Figure 4.5: hsp60-complemented strains are less virulent than clinical isolate 
667 and Erdman Mtb.  
Comparisons of pulmonary (left) and splenic (right) colony forming units (CFU) 
after infection with 667 (blue), DesxH::esxG-esxHA10T-espG3 (green), 
DesxH::esxG-esxHWT-espG3 (orange) or Erdman (black). C57BL/6 mice were 
infected by the aerosol route with a dose of ~100 bacteria per mouse (n=5 
mice/group).  
 
(4) Finally, I made the recombinant esxH alleles using oligo-mediated RecT-
promoted recombineering.  Oligo recombineering was at first an unattractive 
approach due to the need to screen the individual colonies for the successful 
recombination event. The selection of streptomycin resistance would only indicate 
a higher likelihood of integration of the target oligo. Nevertheless, since we 
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employed the “bubble” strategy to avoid MMR, we also took advantage and used 
the bubble sequences as primers in PCR screening. The process became visually 
exciting (to observe a band or not) and less expensive (as opposed to sequencing 
all the candidates). Following the method described in Figure 4.1, we recovered 1 
recombinant out of 9 candidates tested (Figure 4.6). Sequencing confirmed the 
diagnostic PCR results. The successful recombinogenic ErdA10T colony and the 
ErdWT (ie. failed to incorporate esxHA10T but successful at RpsL) were expanded 
and used in our subsequent experiments. 
 
Figure 4.6: Diagnostic PCR screening of nine streptomycin candidates.  
Comparisons of bacterial PCR of streptomycin resistant colonies using either (A) 
the esxHWT forward primer; or (B) the esxHA10T forward primer. In both cases the 
reverse primer for both PCR reactions is 5’ GACGATGCTTAGGCCGACC 3’ from 
espG3 locus, which generates a 1kb DNA fragment.  The sequence of the esxHA10T 
forward primer is 5’ TCATGTACAACTACCCGACC 3’ and esxHWT forward primer 




Earlier we introduced the decoy hypothesis, namely TB10.4-specific CD8 T 
cells do not contribute to the recognition of Mtb-infected cells nor to the control of 
bacterial burden. We were able to assess this hypothesis by determining whether 
the ablation of the TB10.44-11-specific CD8 T cell response (i.e., after ErdA10T 
infection) improved the outcome of infection. Under the conditions we used, no 
differences in bacterial burden were observed between the isogenic ErdWT and 
ErdA10T infected mice. However, since the impact of CD8 T cells is generally 
modest in the presence of CD4 T cells (40), a 30% loss of TB10.44-11-specific CD8 
T cells may not be enough to have an effect on bacterial load in vivo. In addition, 
we learned from Chapter II that MTB32a309-318-specific CD8 T cells did not 
recognize infected macrophages (Figure 2.5). This could also suggest that 
MTB32a is another decoy antigen. Thus, the compensatory gain of MTB32a309-318-
specific CD8 T cells may not have been capable of enhancing host resistance to 
infection.  To further evaluate the decoy hypothesis, we next assessed the 
qualitative differences of T cell responses induced by ErdA10T and ErdWT infection 
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We previously reported that TB10.44-11-specific CD8 T cells do not 
recognize Mtb-infected macrophages and speculated that TB10.4 acts as a decoy 
antigen. In this chapter, I investigate whether polyclonal CD8 T cells following 
infections with clinical isolate Mtb and isogenic strains recognize Mtb-infected 
macrophages differentially. Specifically, we assess the qualitative functionality of 
CD8 T cell responses with or without TB10.44-11 specificity. Our results 
demonstrate that immunodomination by TB10.4 potentially impairs the CD8 T cell 
response to Mtb by diminishing the expansion of other CD8 T cells, some of which 





Mtb infection-elicited CD4 and CD8 T cell responses in both humans and 
animal models are widely appreciated for their role in immunity to control diseases 
(40, 167). Most studies assess the immunogenicity of vaccine by using crude Mtb 
fractions, peptides or recombinant proteins as antigens, presuming that most Mtb 
antigen-specific T cells elicited by natural infection will recognize Mtb-infected 
cells. However, the cell numbers and cytokine responses by antigen-specific T 
cells after stimulation with antigens have not correlated with the protection efficacy 
of vaccines (52, 212). 
We have demonstrated that immunodominant TB10.44−11-specific CD8 T 
cells do not recognize Mtb-infected macrophages (Chapter II and (166)). Other 
studies have shown that CD4 T cells specific for Ag85b240-254, another 
immunodominant antigen, responded poorly in granulomas due to constriction of 
antigen locations (98, 127). Importantly, direct recognition of infected cells by CD4 
T cells is required for optimal control of Mtb infection (97). 
Following aerosol infection, T cells are primed by dendritic cells in lung 
draining MDLN before trafficking back to the lung (41, 43). We consider that the 
antigens presented (or cross-presented) by uninfected DCs in the lymph nodes 
perhaps differ from the antigens presented by infected macrophages in the lung. 
Thus, MDLN-primed T cells may not recognize Mtb-infected cells in the lung. This 
111 
 
could also explain why the number of antigen-specific T cells may not correlate 
with vaccine-induced protection.  
To qualitatively evaluate the differences of T cells elicited from Erdman, 
667, and isogenic ErdWT and ErdA10T infections, we developed modified IFNg 
ELISpot and intracellular cytokine staining (ICS) assays, using a low multiplicity of 
infection (MOI) to assess T cell recognition. By specifically measuring the 
frequency of T cells that recognize Mtb-infected macrophages, this assay could 
provide another criterion to help elucidate the differences in T cell immunity elicited 




Development of Mtb-Infected Macrophage ELISpot and ICS (MIM-E and MIM-
ICS) to assess T cell recognition ability.  
We modified our established in vitro macrophage infection model (166), and 
aimed to maximize the proportion of infected macrophages, preserve macrophage 
viability, and achieve physiologically-relevant low numbers of bacteria per 
macrophage (213) for the Mtb-Infected Macrophage ELISpot (MIM-E) assay. At a 
multiplicity of infection (MOI) of 4, we found that 70% of macrophages were 
infected with 93% viability after 18−24 h (Figure 5.1A, B). In contrast, fewer than 
35% of macrophages were infected at a MOI of 1 (Figure 5.1C). Although 90% of 
the macrophages were infected at a MOI of 20, macrophage viability decreased 
drastically (Figure 5.1C). The median actual MOI was 5 bacteria per macrophage 
and ranged from 2–13 (Figure 5.1D). Thus, a MOI of 4 maximized the percentage 
of infected macrophages while maintaining cell viability. 
To first test the sensitivity of the assay, we diluted ESAT6-specific CD4 T 
cells (hereafter, C7 T cells) into an excess of naive splenic T cells from uninfected 
C57BL/6 mice, and performed an IFNg enzyme-linked immunospot (ELISpot) 
assay to measure the frequency of T cells that recognize Mtb-infected 
macrophages. Minimal cytokine production of C7 T cells occurred when culturing 
with uninfected macrophages (Figure 5.1E). The naive C57BL/6 T cells produced 
undetectable amount of IFNg when cultured with infected macrophages or ESAT63-
113 
 
17 peptide-pulsed uninfected macrophages (data not shown). When the C7 and 
naive T cell mixture was co-cultured with Mtb-infected macrophages, we observed 
IFNg spots at ~40−50% yield of the input C7 cells, and the ELISpot assay 
sensitively detected as low as 0.04% of C7 present in the total T cells (Figure 5.1E). 
When ESAT63−17 cognate peptide was supplemented, ~150 spots per 200 C7 T 
cells produced IFNg (i.e., 70 −80% of input C7 T cells in Figure 5.1E). Application 
of the assay to Ag85b-specific CD4 T cells (hereafter, P25 T cells) showed that 
over 50% of the P25 T cells that recognized Ag85b240-254 cognate epitope could 
recognize Mtb-infected macrophages (Figure 5.1F). 
We next adapted the MIM-E assay for a flow cytometry-based technique. 
Pulmonary T cells from infected mice were cultured with Mtb-infected 
macrophages and analyzed by both ELISpot (MIM-E) and intracellular cytokine 
staining (MIM-ICS) in parallel. Both assays resulted in similar frequencies of CD4 
and CD8 T cells that produced IFNg in response to Mtb-infected macrophages 
(Figure 5.2A-C).  
Based on our results, the Mtb-Infected Macrophage ELISpot (MIM-E) and 
ICS (MIM-ICS) represent two sensitive and specific approaches to identify T cells 









Figure 5.1: Measuring T-cell recognition by the Mtb-infected macrophage 
ELISpot (MIM-E) 
(A-B) After infection with H37Rv or Rv.YFP at an MOI of 4 for 18 h, CD11b+ purified 
thioglycolate-elicited peritoneal macrophages (TGPM) were measured for the 
percentage of cells that were (A) infected and (B) viable. (C) TGPM were infected 
with Rv.YFP at MOI of 1, 4 or 20, for 18−24 h and the percentage of infected 
macrophages and cell viability were assessed. (D) The actual MOI was determined 
by plating CFU. (E) The Mtb-infected macrophage ELISPOT (MIME) assay was 
performed by infecting macrophages with H37Rv at an MOI of 4, for 18−24 h. A 
titrated number of C7 T cells were mixed with polyclonal T cells (105/well) from 
uninfected mice and added to Mtb-infected macrophages (105/well). The ESAT-63-
17 peptide was added to the wells, indicated in blue. (F) MIME assay was 
performed with P25 T cell line. UI indicated uninfected macrophages, Mtb for Mtb-
infected macrophages, pep for Ag85b240-254 peptide, and aCD3 for soluble anti-
CD3 mAb. Two independent experiments are shown. Each experiment was 
normalized by subtracting the background and defining the aCD3 response as the 
maximal (i.e., 100%) response. Data are representative of two independent 
experiments with three technical replicates per experiment that yielded similar 
results (A, B, C, E, F), or 12 independent experiments with three technical 







Figure 5.2: Similar frequencies of T cells recognizing Mtb-infected 
macrophages are detected by the MIM-E assay and MIM-ICS.  
Purified pulmonary CD4 or CD8 T cells were cultured with Mtb-infected 
macrophages, subjected to intracellular cytokine staining (ICS) and analyzed by 
flow cytometry. (A) Representative flow plots showed the frequency of pulmonary 
CD4 (left column) or CD8 (right column) T cells expressing CD69 and producing 
IFNg after 6-hour culture with macrophages with (top row) or without (bottom row) 
Mtb infection. (B-C) The MIM-E or the Mtb-infected macrophage-ICS (MIM-ICS) 
assay were used to calculate the frequency of CD4 (B) or CD8 (C) pulmonary T 
cells that recognized Mtb-infected macrophages. U indicated uninfected 
macrophages, Mtb indicated Mtb-infected macrophages, and n.s. signified not 
significant (t test).   
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CD4 and CD8 T cells differ in their ability to recognize Mtb-infected 
macrophages 
Total of T cell recognition of individual Mtb antigens should hypothetically 
be similar to that of Mtb-infected macrophages. To assess this assumption, we 
took advantage of the megapool of 300 peptides (p300) representing 90 antigens 
frequently recognized by human CD4 T cells from healthy IGRA+ individuals (214). 
The p300 peptide pool contains epitopes that are also recognized by murine CD4 
and CD8 T cells (based on data available in the IEDB). The advantages of the 
megapool over other crude Mtb antigens such as PPD, culture filtrate proteins or 
Mtb lysate are the equimolar concentrations among all epitopes, and that the 
epitopes are in the form of peptides rather than proteins, allowing efficient 
presentation by class I MHC. We compared IFNg production by pulmonary T cells 
from C57BL/6 mice of 4-week post Erdman Mtb infection with H37Rv-infected 
macrophages or the p300 megapool. The CD4 T cell response was higher toward 
Mtb-infected macrophages than to the p300 megapool (Figure 5.3A), indicating 
that the p300 megapool does not represent all epitopes presented by Mtb infection 
of murine macrophages. In contrast, CD8 T cells responded better to p300 
megapool stimulation (Figure 5.3A). The skewed CD8 T cell response suggested 
the mismatched repertoire of antigens used to prime CD8 T cells (such as 
TB10.41−15 of p300) compared to the antigens presented by Mtb-infected cells. In 
addition, the proportion of IFNg producing CD4 T cells was higher than that of CD8 
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T cells, indicating that polyclonal CD4 T cells recognize Mtb-infected cells better 
than polyclonal CD8 T cells at the peak of infection (Figure 5.3A).  
The number of intracellular Mtb could impact how much CD4 and CD8 T 
cells can recognize the infected macrophages. A study by Lewinsohn et al. showed 
that a human CFP10-specific CD8 T cell clone only recognized DCs with high 
numbers of infecting bacteria (179). To determine whether the bacterial dosage 
affects polyclonal T cell recognition, we performed MIM-ICS assay of purified CD4 
and CD8 T cells from the lungs of infected C57BL/6 mice with infected 
macrophages using a range of MOIs. Polyclonal CD4 T cells readily recognized 
infected macrophages and produced IFNg at a low MOI of 0.2, while the recognition 
increased at a MOI of 1.2 and plateaued at a MOI of 5.8 (Figure 5.3B). In contrast, 
polyclonal CD8 T cells did not significantly recognize Mtb-infected cells at low MOI 
of 0.2 and 1.2, but required a higher MOI for recognition and IFNg production. 
(Figure 5.3B). This result indicated that pulmonary CD4 T cells recognize Mtb-







Figure 5.3: Differences in CD4 and CD8 T-cell recognition of Mtb- infected 
macrophages. 
(A) CD4 (left) and CD8 (right) T cells obtained from Mtb-infected C57BL/6 mice 
were assessed for their recognition of Mtb-infected macrophages or the 300 
peptide megapool (p300) by MIM-ICS. Data was shown from two independent 
experiments (signified by open or closed symbols), each with five mice/group, 
analyzed 4 wpi. (B) The frequency of pulmonary CD4 and CD8 T cells that 
produced IFNg upon stimulation with Mtb-infected macrophages were determined 
by ICS. The target MOIs were indicated and the actual MOIs were shown in 
parentheses. Data are representative of two independent experiments using T 
cells from five individual mice at 4 or 22 weeks post-infection. Each line represents 
an individual mouse. The statistical test was a two-way ANOVA with Tukey’s post-
test; actual p values are shown.  
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Differential recognition of Erdman- and 667- elicited CD8 T cells 
We previously showed that TB10.44-11-specific CD8 T cells do not recognize 
infected macrophages (Chapter II and (166)). Given the dominance of the TB10.44-
11-specific CD8 T cell response in the lung, we hypothesized that TB10.4 may be 
acting as a decoy antigen. Our finding that following 667 infection—few TB10.44-
11-specific CD8 T cells were detected and instead, a greater expansion of MTB32a-
specific CD8 T cells were elicited—supported this idea (Figure 3.2). Therefore, we 
asked whether the abrogation of the immunodominant TB10.44-11 epitope resulted 
in an expansion of CD8 T cells that recognized Mtb-infected macrophages. To test 
this hypothesis, we quantified T cell recognition of Mtb-infected macrophages by 
the MIM-ICS assay. CD4 T cells from Erdman- or 667-infected C57BL/6 mice 
recognized H37Rv-infected and 667-infected macrophages similarly, and in a 
dose-dependent manner (Figure 5.4A, B). Thus, these two bacterial strains elicit 
CD4 T cell responses that had a similar capacity to recognize infected 
macrophages; both in vitro infections were successful, and the antigen 
presentation of class II MHC was not different between 667- and H37Rv-infected 
macrophages. There was little or no recognition of infected macrophages by CD8 
T cells at a low MOI, as previously shown (Figure 5.3). Contrary to our prediction, 
Erdman-elicited CD8 T cells, but not 667-elicited CD8 T cells, recognized H37Rv-
infected macrophages at a high MOI (Figure 5.4C). When the reciprocal 
experiment of CD8 T cells from Erdman- or 667-infected mice to recognize 667-
infected macrophages was measured, neither Erdman nor 667-elicited CD8 T cells 
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significantly recognized 667-infected macrophages (Figure 5.4D). While these 
experiments do not support the decoy hypothesis, the results of lower IFNg 
responses of 667-elicited CD8 T cells and lower stimulation of 667-infected 
macrophages show how the mycobacterial strain, or possibly lineage, can 





Figure 5.4: MIM-ICS assay of T cells elicited from Erdman and 667 infection 
reveals differential recognition capability.  
CD4 (A, B) or CD8 T cells (C, D) purified from the lungs of Erdman- or 667-infected 
mice were cultured with H37Rv-infected (A, C) or 667-infected (B, D) macrophages 
and the MIM-ICS assay was performed. The X axis is the actual multiplicity of 
infection (MOI) as determined by CFU plating. Results from two different 
experiments are pooled and plotted on each graph. Each box and whisker plot 
represent results from 5 individual mice, with 2 experimental replicates shown. 
Statistical significance was determined by multiple t testing, and p values <0.05 
are shown above the bars.  
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ErdWT- and ErdA10T-elicited CD8 T cells inefficiently recognize macrophages 
with different Mtb strain infections 
667-elicited CD8 T cells recognized H37Rv infection less than their Erdman-
elicited counterparts, but by using 667-infected macrophages, we considered that 
there may be a defect in class I MHC presentation and T cell priming during in vivo 
667 infection (Figure 5.4). To investigate this possibility, we sought to determine 
the recognition capabilities of pulmonary T cells between the isogenic ErdWT and 
ErdA10T infections using MIM-ICS assay. Similar to the observation of ex vivo 
Erdman- and 667-elicited CD4 T cells, we detected the comparable capability of 
polyclonal CD4 T cells from ErdWT and ErdA10T infections in recognizing infected 
macrophages regardless of the bacterial strain used for macrophage infections 
(Figure 5.5A). This observation persisted throughout the course of infection as the 
ex vivo polyclonal CD4 T cells from mice at 19 weeks post-infection recognized 
Mtb-infected macrophages equivalently (Figure 5.5E, F). When considering CD8 
T cells, however, the recognition capability of early-induced ex vivo CD8 T cells 
was different from that of the CD8 T cells isolated later in infection. At 6 weeks 
post-infection, both CD8 T cells recognized ErdWT-infected macrophages similarly. 
In contrast, ErdA10T-elicited CD8 T cells produced IFNg in response to ErdA10T-
infected macrophages significantly better than ErdWT-elicited CD8 T cells (Figure 
5.5B-D). At 19 weeks post-infection, despite the similar trend observed, ErdWT- and 
ErdA10T-elicited CD8 T cells did not recognize infected macrophages differentially 
(Figure 5.5G-H).  
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Since we detected slight preferential responses of ErdWT-elicited CD8 T 
cells to ErdWT-infected macrophages and ErdA10T-elicited CD8 T cells to ErdA10T-
infected macrophages, we wished to confirm our previous observation that infected 
macrophages did not present the TB10.4 epitope (166). We used DesxH Mtb strain 
for macrophage infection and observed the MIM-ICS+ proportions to be similar 
between ErdWT- and ErdA10T-elicited CD4 and CD8 T cells (Figure 5.6I-J), 
indicating that the T cells that recognize infected macrophages were not TB10.4-
specific.  
Together, these findings show that polymorphic Mtb can induce different T 
cell immune responses that lead to differential recognition ability. CD8 T cells that 
contribute to recognition are not TB10.4-specific, supporting the hypothesis that 
TB10.4 is a decoy antigen. Yet, how much CD8 T cells can recognize and 










Figure 5.5: Isogenic ErdWT and ErdA10T infections elicit CD8 T cell responses 
that differentially recognize infected macrophages early during infection.  
C57BL/6 were aerosol infected with ErdA10T or ErdWT Mtb and analyzed by MIM-
ICS assay for recognition capabilities as described earlier. Percent IFNg+ 
populations of CD4 (A, E, F, I) and CD8 (B, C, D, G, H, J) T cells at 6 weeks (A-D) 
and 19 weeks (E-J) post isogenic in vivo infection were presented with actual 
macrophage in vitro infection doses on x axes. Macrophages were infected with; 
H37Rv (A, B); ErdWT (C, E, G); ErdA10T (D, F, H); and DesxH (I, J). Data are 
representative of two experiments. Each experiment was performed with 5 mice 
per group. Statistical testing by a two-tailed, unpaired Student’s T test with Holm-







We developed the MIM-E and MIM-ICS assays to quantify T cells that 
recognize Mtb-infected macrophages. To mimic the physiological conditions of 1–
5 bacteria per infected cell in the lungs (213), we achieved a median MOI of 5. 
Under these conditions, 70% of macrophages are infected with 93% viability. The 
proportion of infected cells is crucial because bystander or uninfected cells have 
been shown to present antigens released from Mtb-infected cells or from dying 
cells (122, 130, 133, 134). Therefore, the maximized infection rate allowed us to 
study the direct recognition of Mtb-infected cells. 
In Chapter II of this dissertation, we reported that TB10.44-11-specific CD8 T 
cells do not recognize infected macrophages [Figure 2.2 and (166)]. Together with 
a discrepancy between the fraction of T cells that recognize peptide epitopes 
versus Mtb-infected macrophages (Figure 5.3), we inferred that: (1) the ~10% of 
total CD8 T cells that recognize Mtb-infected macrophages in C57BL/6 are specific 
for unknown antigens; and, (2) CD8 T cell epitopes may not be efficiently 
presented by Mtb-infected macrophages (but are overrepresented in the p300 
peptide pool). Although the p300 peptide pool was generated from known human 
class II MHC-restricted epitopes and species differences could impact the results, 
we predict that if a C57BL/6-specific peptide pool was available, a larger difference 
between the recognition of antigens versus the Mtb-infected macrophages would 
be observed. In addition, we find that CD4 T cells detect Mtb-infected 
macrophages more efficiently at a lower MOI than CD8 T cells which required more 
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heavily infected cells. This finding agrees with a previous report showing human 
CD8 T cell clones preferentially recognize heavily infected DCs (179). 
To decipher the decoy hypothesis and understand whether a CD8 T cell 
response without TB10.44-11 specificity would enhance the recognition, we 
evaluated the IFNg production of T cells elicited by Erdman infection in comparison 
to 667 infection, and ErdWT to ErdA10T infections. Regardless of the bacterial strain 
used during in vivo and in vitro infections, polyclonal CD4 T cells all recognized 
infected macrophages similarly. To our surprise, 667-elicited and ErdA10T-elicited 
CD8 T cells behaved differently in a manner that was opposite from what we would 
have predicted based on the decoy hypothesis. Fewer 667-elicited CD8 T cells 
recognized H37Rv-infected macrophages than Erdman-elicited CD8 T cells. 
However, we gained insight from the 667-infected macrophages stimulation 
condition which poorly induced CD8 T cell responses, suggesting an overall defect 
in class I MHC antigen presentation by 667-infected cells. In support of the decoy 
hypothesis, CD8 T cells elicited from ErdA10T infection recognized ErdA10T-infected 
cells better than ErdWT-elicited CD8 T cells. However, their ability to recognize is 
context dependent: no differences were observed with ErdWT-infected 
macrophages or when T cells were obtained from chronically infected mice.  
Furthermore, as we determine that MTB32a309-318-specific CD8 T cells do not 
recognize Mtb-infected macrophages (Figure 2.5), the compensatory increase in 
the frequency of MTB32a309-318- specific CD8 T cells observed after 667 or ErdA10T 
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infection is unlikely to lead to better recognition of Mtb-infected cells. Rather, Mtb 
could exploit immunodomination as the decoy mechanism. 
As the isogenic-infected C57BL/6 mice exhibited similar bacterial burdens 
in the lungs and comparable dissemination to the spleens (Figure 4.4), we cannot 
correlate MIM-ICS+ CD8 T cells with in vivo bacterial loads. Since direct CD4 T cell 
recognition of infected cells is required for bacterial control in vivo (97), it is likely 
that MIM-ICS+ CD4 T cells recognize Mtb-infected cells and provide protection in 
vivo. Interestingly, we observed a modest increase in the frequency of MIM-ICS+ 
T cells during the chronic phase of infection (Figure 5.5B versus C), even though 
these T cells may become dysfunctional (69) or suboptimally interact with infected 
APCs because they fail to enter the lung parenchyma (215, 216). Therefore, 
following the initial activation and subsequent contraction of T cells without antigen 
stimulation, the efficiently recognizing cells could be enhanced in their fraction and 
representation in the MIM-ICS+ population.  
A limitation of this first version of MIM-E and MIM-ICS is its focus on IFNg. 
Despite being the central dogma of protective immunity against TB, IFNg does not 
always correlate with protection (52-54) and there are currently no correlates of 
protection in tuberculosis. Other cytokines such as IL-2, IL-17, and TNFa are 
produced by T cells after TCR activation; therefore, both the MIM-E and MIM-ICS 
assays can be adapted to include more cytokines. Another limitation is the duration 
of the assays, which are limited to the first 48 hours of in vitro infection. For 
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example, the expression of Ag85B varies during the course of infection, but 
importantly, is downregulated after three weeks post-infection (68, 127). As we are 
only measuring the antigens presented by macrophages within the first 48 hours 
of in vitro infection, we may fail to detect T cells that recognize antigens that are 
only expressed in the lung or late during infection.  Lastly, the use of thioglycolate-
elicited macrophages could lead to bias. Antigen-presentation by macrophages 
and DCs have some important differences, including the rate of protein 
degradation in the phagosomes. Macrophage phagosomes are more degradative 
than DC phagosomes, potentiating the differences in antigen presentation (217, 
218). Since macrophages play an important role in Mtb biology and disease 
progression (219-221), we opted to assess T cell recognition of Mtb-infected 
macrophages. Many human and murine studies use Mtb-infected DCs and report 
very low frequencies of lymph node and lung T cells that recognized Mtb-infected 
DCs (89). 
Other studies have shown that after in vitro expansion, human and murine 
CD8 T cell lines recognize and kill Mtb-infected DCs or macrophages (179, 222-
225). These studies have been useful for characterizing antigen specificity and T 
cell functions but cannot deduce the ex vivo frequency of T cells that recognize 
infected macrophages. Further information is limited concerning the capacity of ex 
vivo T cells to recognize Mtb-infected cells (79, 89, 175, 179, 222-225). Barriers to 
these experiments include the low frequency of antigen-specific T cells in human 
blood and technical difficulties using live Mtb-infected cells. Possible confounders 
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also include the use of total lung cells instead of purified T cells and the 
dependence on blocking antibodies against class II and class I MHC to estimate 
the frequencies of CD4 and CD8 T cells that recognize Mtb-infected DCs. 
However, using class II MHC blocking antibodies does not exclude the noncognate 
activation of CD4 T cells (169).  
The differential recognition of Mtb-infected macrophages by CD8 T cells 
generated from in vivo infections with different bacterial strains show that bacterial 
polymorphisms can have important effects on immunogenicity.  The unexpected 
results of 667-elicited and ErdA10T-elicited CD8 T cells argue against the decoy 
hypothesis that focuses particularly on the TB10.4 protein. We, therefore, propose 
that immunodomination could be a decoy mechanism for immune evasion, by 
which Mtb elicits large antigen-specific responses that do not contribute to 
recognition of Mtb infection, but inhibit the generation of CD8 T cell responses to 
other mycobacterial antigens. A more comprehensive study to elucidate the 
epitopes presented by Mtb-infected cells, using a variety of bacterial strains, will 
be critical to better understanding the extent of this hypothetical evasion strategy, 
but also to identify Mtb antigens presented by infected cells. Finally, as we believe 
that recognition of Mtb-infected macrophages by vaccine-elicited T cells will be a 
prerequisite to protection, we expect that the MIM-E and MIM-ICS assays will 
complement other approaches to assess T-cell-based vaccine candidates.   
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CHAPTER VI: DISCUSSION 
“To know the history of science is to recognize the mortality of any claim to 
universal truth,” said Evelyn Fox Keller, a physicist (and feminist) at Massachusetts 
Institute of Technology. Previous findings that have led to new development and 
scientific discovery are extensively indispensable. Yet, flexibility in understanding 
is crucial to allow new and old ideas to be questioned, contradicted and accepted. 
In this dissertation, Mtb-specific and infection-elicited polyclonal CD4 T cells have 
been confirmed for their importance during tuberculosis. We observed a higher 
proportion of infection-driven CD4 T cells in recognizing Mtb-infected 
macrophages than that of CD8 T cells throughout the experiments in Chapter V. 
However, the highly responsive CD4 T cells only led to the stabilization of bacterial 
burden and did not further reduce bacterial burden. We, therefore, challenge the 
dogma that CD4 T cells are the critical component of T cell immunity against 
Mycobacterium tuberculosis infections, and propose—based on our finding—that 
Mtb evades CD8 T cell immunity and CD8 T cells would have the potential to 
eliminate infection if their functions were not subverted. 
Immunodomination, an immunological phenomenon described as the 
suppression of subdominant responses by an immunodominant antigen-specific 
CD8 T cell response, has been observed in many viral models (136-139). However, 
immunodomination has never been reported during bacterial infection. Even 
though many robust immunodominant Mtb-specific CD8 T cell responses have 
been reported in humans and mice, CD8 T cell contribution to protective immunity 
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against Mtb infection has been largely inefficient. Thus, we hypothesize that 
immunodomination could act as the decoy mechanism used by Mtb to diminish the 
generation of CD8 T cells that are specific to other Mtb antigens, some of which 
can provide protection.  
 
Figure 6: Immunodomination is a decoy mechanism Mtb used to evade CD8 
T cells  
Mtb (red rods)-infected cells transfer diverse class I MHC epitopes to bystander 
uninfected cells. The bystander cells subsequently induce high proportions of CD8 
T cells that can only recognize uninfected cells. Consequently, a small proportion 





We speculate that the decoy mechanism may be the consequence of Mtb 
in infected cells actively inhibiting class I MHC antigen presentation. In turn, only 
uninfected cells can present Mtb antigens. Since the definition of an effective 
immune response includes not only the containment but also the clearance of Mtb 
infection, supporting evidence of the decoy hypothesis would comprise limited 
abilities of immunodominant CD8 T cells to both recognize and kill Mtb-infected 
cells.  Polyclonal CD8 T cells without specificity for immunodominant epitopes are 
also expected to have greater capabilities in recognizing and killing Mtb-infected 
cells. Vice versa, if the decoy hypothesis does not occur, we anticipate the 
recognition ability of CD8 T cells without specificity to immunodominant epitopes 
could either worsen or remain unaffected. 
To assess the hypothesis, we first evaluated the immunodominant CD8 T 
cell responses in Mtb-infected C57BL/6 mice, whereby 30% of CD8 T cells are 
specific for a single TB10.44-11 epitope. Supporting the decoy hypothesis, TB10.44-
11-specific CD8 T cells did not recognize Mtb-infected macrophages nor control 
Mtb growth [Figure 2.2 and (166)]. Using mice with different genetic backgrounds 
and MHC haplotypes that present different Mtb epitopes, we investigated the 
recognition capability of TB10.420-28-specific CD8 T cells that are generated during 
Mtb infection in BALB/c mice (157). We showed that TB10.420-28-specific CD8 T 
cells, elicited by vaccination, also did not recognize Mtb-infected macrophages 
(Figure 2.4).  
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Our lab has reported the phenomenon we termed immunofocusing during 
Mtb infection in BALB/c mice (157). In this study, we highlighted the 
immunodominant CD8 T cell response against the TB10.420-28 epitope and a 
subdominant CD8 T cell response against the EspA150-158 epitope during the 
natural course of Mtb infection in BALB/c mice. When a subdominant EspA150-158-
specific CD8 T cell response was primed by vaccination using recombinant 
vaccinia expressing the EspA gene, a memory CD8 response to EspA was elicited 
and transiently boosted following challenge with Mtb. However, by four weeks after 
infection, the hierarchy of dominant TB10.420-28-specific CD8 T cell response was 
restored and persisted throughout the remainder of the infection. This also resulted 
in unchanged bacterial burden. In retrospect, considering the requirement of direct 
engagement and recognition of the infected cells for killing (97), the inability of 
TB10.420-28-specific CD8 T cells to directly recognize infected macrophages 
(Figure 2.4) potentially explains why TB10.420-28-specific memory CD8 T cells 
failed to mediate protection. 
We sought to identify CD8 T cells with known antigen specificity that can 
recognize Mtb-infected cells in order to study the protective functions and effects. 
We chose MTB32a309-318, a different CD8 T cell epitope from an independent 
protein. This epitope was selected because MTB32a is a component of the 
promising M72/AS01 vaccine and we can detect a subdominant response of 
MTB32a309-318-specific CD8 T cells in Mtb-infected C57BL/6 mice. However, we 
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have shown that MTB32a309-318-specific CD8 T cells, elicited by vaccination, also 
do not recognize infected macrophages (Figure 2.5) 
The failure of two immunodominant and one subdominant CD8 T cell 
responses from two different mouse strains to recognize Mtb infected cells raises 
the possibility that this is a general feature of CD8 T cell responses and not unique 
to a particular epitope or host genetic background. Remarkably, C57BL/6 and 
BALB/c mice are more resistant to Mtb infection than C3H mice (226, 227), but the 
majority of CD8 T cells in Mtb-resistant mice do not recognize Mtb-infected cells 
[Chapter II, V, and (166)]. In addition, it has been shown that the intrinsic 
susceptibility of C3H mice is due to a delay in the CD8 T cell response (41); 
induction of an earlier CFP10-specific CD8 T cell response through vaccination 
lowers their susceptibility (228). This further supports the idea that Mtb could 
dampen the contribution of CD8 T cells in protection. The remaining questions are 
whether CFP10-specific CD8 T cells and what proportion of polyclonal CD8 T cells 
from Mtb-susceptible C3H mice recognize Mtb-infected cells. The frequency of 
CD8 T cells that recognize infected macrophages could also be examined in the 
newly identified Mtb-susceptible and Mtb-resistant collaborative cross (CC) 
diverse inbred mouse strains (25) to gain more insights into the contribution of CD8 
T cells in protective T cell responses.  
Therefore, chapter II has demonstrated that during Mtb infection, infection-
driven immunodomination may be responsible for the failure of vaccination to 
137 
 
promote better control of infection. We have now observed this phenomenon after 
vaccination with four distinct CD8 T cell epitopes [(157, 160) and unpublished].   
The most direct approach to study immunodomination is to eliminate the 
immunodominant response. However, the gene encoding TB10.4 protein, esxH, is 
an essential gene, and Mtb with esxH deficiency are attenuated in vivo. Generally, 
pathogens evolutionarily conserve their essential genes for survival, but esxH is 
surprisingly highly polymorphic. As Mtb is an obligate human pathogen, the 
antigenic variation suggests an ongoing adaptation to the host immune pressure. 
This is particularly exciting because the esxH hyperpolymorphism is focused only 
in lineage 1 of Mtb. Together with the geographical clustering of both Mtb lineage 
and class I MHC—the most polymorphic allele in human genome (229)—we may 
be observing evidence of ongoing immune evasion during Mtb-human co-
evolution.  
To overcome the attenuation of Mtb with esxH deficiency and broaden the 
understanding of esxH polymorphisms, we employed a clinical isolate with a 
naturally occurring esxH polymorphism to study the impact of immunodomination 
of TB10.4-specific CD8 T cells responses in C57BL/6 mice. We demonstrated a 
switch in the immunodominant antigens through infections with the clinical isolate 
667 containing a single A10T amino acid substitution in the TB10.4 protein. I 
subsequently generated isogenic Mtb strains expressing EsxHA10T or EsxHWT and 
revealed the immunodomination phenomenon during Mtb infection through 
EsxHA10T. MTB32a309-318-specific CD8 T cells became the immunodominant 
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response in the absence of TB10.44-11-specific CD8 T cells during 667 and ErdA10T 
infection (Figure 3.2 and 4.2). When examining the cause further using in vitro 
assays, we observed the preserved recognition ability of TB10.44-11-specific CD8 
T cells to the cognate “WT” and polymorphic A10T epitopes, and the A10T epitope 
was able to bind and present on H-2Kb (Figure 3.4). Through a collaboration with 
Dr. Sylvie Le Gall, an A10T long peptide was shown to be digested faster and finer 
than the wild-type counterpart. Thus, we hypothesize that the loss of TB10.44-11-
specific CD8 T cell response is due to a decreased amount of the epitope 
presented. Despite yet-to-be-identified specific mechanisms, the EsxHA10T variant 
has been shown to change the hierarchy of antigen-specific immune responses. 
The finding of increased MTB32a309-318-specific CD8 T cells was serendipitous 
because, aside from H-2Kb/TB10.44-11 tetramer, H-2Kb/MTB32a309-318 tetramer 
was the only Mtb-specific tetramer available for H2b restriction. We, therefore, 
speculate that there are potentially more changes in other Mtb-specific epitopes 
and that the loss of TB10.44-11-specific response may allow the space for other 
antigen-specific cells to expand. 
To evaluate whether TB10.4 acted as a decoy antigen to distract host 
immunity from generating protective responses, we utilized 667 and ErdA10T Mtb to 
assess whether host immunity without TB10.44-11-specific CD8 T cells could 
recognize infected macrophages better in Chapter V. Contrary to the decoy 
hypothesis, we did not observe different bacterial burdens following ErdWT and 
ErdA10T infections. However, given that Mtb may suppress CD8 T cell functions, a 
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30% change of CD8 T cell antigen specificity might not display in protection. In 
addition, we have determined that MTB32a309-318-specific CD8 T cells do not 
recognize infected macrophages (Figure 2.5), suggesting that MTB32a could also 
act as another decoy antigen. Taken together, the correction of immunodominant 
CD8 T cell responses might not lead to the control of Mtb infection. 
This highlights our finding that not all T cell responses elicited by Mtb 
provide benefits to the host [Chapter V, (166, 169)]. Even though TB10.4 is highly 
variable, and its polymorphism results in a change in hierarchy of the antigen-
specific CD8 T cell responses, the compensatory response of a different decoy 
immunodominant epitope could still result in a benefit toward Mtb rather than the 
host. The decoy hypothesis supports the notion that T cell responses may provide 
a survival advantage for the bacterium (110, 111); by generating T cells that lack 
recognition and clearance abilities, T cell responses may accompany inflammation 
and pathology that create an environment to permit bacterial growth and 
transmission. Thus, Mtb focuses the CD8 T cell response on the immune response 
that may not contribute to the bacterial control, successfully evading T cell 
immunity and enabling it to establish a persistent infection.  
Studies of the TB10.4 protein are complicated because of its role in 
impairing the ESCRT pathway and affecting class II MHC presentation (113, 126). 
On the one hand, we do not suspect the A10T substitution of TB10.4 protein affects 
its essentiality and reported function, but the polymorphisms reveal regions that 
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can be modified instead. We found that H37Rv lab strain and ErdWT Mtb did not 
interfere with class I or II MHC presentations in infected macrophages as the 
polyclonal CD8 and CD4 T cells could produce IFNg in response. In addition, we 
observed that polyclonal CD4 and CD8 T cells produced IFNg in response to 
ΔesxH Mtb-infected macrophages. When using complemented ΔesxH::esxHWT or 
ΔesxH::esxHA10T strains for macrophage infections, we did not observe a decline 
of recognition by polyclonal CD4 or CD8 T cells. On the other hand, at similar 
infecting doses to H37Rv and ErdWT Mtb, stimulations with clinical isolate 667- and 
isogenic ErdA10T-infected macrophages exhibited a reduction in the proportion of 
responsive CD8 T cells, suggesting impaired class I MHC presentation. Thus, our 
data do not agree with the idea that TB10.4 function is detrimental to class II MHC 
antigen presentation. Rather, the EsxHA10T polymorphism has more impact on 
class I MHC. However, the differences between the studies include 1) infection 
protocols: both the length of infection and the length of co-culture, and 2) the 
macrophages used in the studies: TGPMs vs. BMDMs. Furthermore, ΔesxH Mtb 
has defects in intracellular growth, so the finding that CD4 T cells mediate better 
bacterial reduction perhaps have been partially helped by the enhanced killing by 
innate macrophage antimicrobial mechanisms (126).  
The experimental setup to assess the recognition capabilities of polyclonal 
CD8 T cells from 667, ErdWT and ErdA10T in vivo infections were complex and, 
therefore, made interpreting the results difficult. Although a few conclusions can 
be inferred, results may be interpreted differently depending on further in vivo 
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characterization of bacterial burden and kinetics. Therefore, to fully understand the 
qualitative differences of CD8 T cell responses elicited by polymorphic Mtb 
infections, further studies are needed to include more phenotypic markers. To 
identify the polyclonal CD8 T cell responses that contribute to the recognition of 
infected cells, one could sort IFNg-secreting cells using a Miltenyi recombinant 
antibody that is bi-specific to CD45 and IFNg. The sorted cells could subsequently 
be TCR sequenced, examined for antigen specificity, and derived into a polyclonal 
cell line that can recognize Mtb infection. In addition, the purified CD8 T cells could 
also be analyzed by single cell RNASeq to compare molecular functional 
differences of elicited CD8 T cells and to investigate other cell subsets. In parallel, 
immunopeptidomic analysis to identify epitopes presented on Mtb-infected and 
uninfected macrophages will enhance the possibility of distinguishing antigens for 
future studies. Identification of presented epitopes and the responsive T cells could 
lead to the generation of protective immunity and overcome the decoyed immune 
responses. 
We used IFNg production to study the recognition ability of elicited 
polyclonal CD8 T cells in Chapter V. However, the effector functions and the ability 
to kill Mtb-infected cells were not determined. To further evaluate the bacterial 
control functions of differentially elicited CD8 T cells, one could perform an 
adoptive transfer experiment of isogenic-elicited CD8 T cells into Mtb-infected 
recipients and determine the bacterial burden. The depletion of CD8 T cells in 
isogenic-infected mice may also help determine survival differences based on the 
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contribution of a different repertoire of CD8 T cell specificities. To test the protective 
impact of cross-recognition of CD8 T cells from ErdA10T to ErdWT-infected 
macrophages (and the inability of CD8 T cells from ErdWT to recognize ErdA10T-
infected macrophages), one could infect mice with ErdA10T or ErdWT Mtb, treat with 
antibiotics to clear the infections, and challenge with the reciprocal strain to 
determine the antigen-specific CD8 T cell responses and bacterial burden. 
We recognize that the C57BL/6 murine model cannot represent what 
happens during human infection, and the wide polymorphisms of class I MHC in 
humans contributes to the possibility that this phenomenon might not occur in 
people. Despite no differences in bacterial burden following infection with isogenic 
strains, a pathology study could be used to determine if inflammation differs. One 
could use the clinical isolate or isogenic Mtb strain to infect a different animal 
model, such as monkey, to induce more distinct granuloma phenotypes and 
compare the pathological outcomes. 
Nevertheless, Chapter III and IV showed that a single amino acid 
substitution can alter host immune response drastically. With the heterogeneity of 
clinical Mtb isolates in the human population, the apprehension that Mtb-induced 
immunodominance will supersede a vaccine-driven response poses a question 
about the current vaccine strategies in development. In addition, since people with 
a history of Mtb infection and antibiotic treatment are able to get reinfected with 
Mtb, Mtb-elicited immune responses may be inefficient due to Mtb’s arsenal of 
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immune evasion strategies. As immunological space is conceptually limited (230, 
231), considering whether there are cross-reactivities among existing immune 
responses from BCG vaccinated, previously infected and subsequently cured, and 
currently infected individuals will be critical for the development of efficacious new 
treatments.  
 What constitutes protective immunity against tuberculosis is not fully 
understood and is reflected in the lack of immune correlates of protection. This 
knowledge gap has hampered the development of an effective vaccine. Since 
direct engagement and recognition of TCRs to the infected cells are required for 
killing of infected cells (97), successful vaccines should be able to induce CD4 and 
CD8 T cells that can recognize infected, rather than uninfected, cells. A recent 
study using immunopeptidomic analysis to identify epitopes presented on BCG-
infected macrophages showed that only a small subset of peptides consistently 
presented in 4 different replicates (232). Since BCG, but not Mtb, infections are 
generally subjected to clearance by CD4 and CD8 T cell immunity, epitopes 
presented on the Mtb-infected macrophages may be even more diverse to escape 
T cell recognition. Successful vaccines should also be able to induce a broad 
repertoire of CD4 and CD8 T cells that can recognize (possibly diverse) epitopes 
presented on infected cells. 
Numerous microbial and host factors determine whether a protein from an 
intracellular bacterium elicits a T cell response. These include the bacilli’s 
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intracellular niche, the protein’s abundance, and whether it is secreted. Many T 
cell-based vaccine studies assume that Mtb-specific T cells elicited by natural 
infection will recognize infected cells. Consequently, such T cells elicited by 
vaccination should mediate protection against Mtb. The failure of TB10.44-11- and 
TB10.420-28-specific CD8 T cells to recognize Mtb-infected macrophages 
demonstrated that not all Mtb-specific T cells recognized Mtb-infected 
macrophages (98, 122, 127, 166). Consistently, the AERAS-402 vaccine 
expressing Mtb antigens elicited CD8 T cells that failed to recognize or only 
modestly recognized Mtb-infected DCs (165). This further emphasizes the 
possibility that some Mtb antigens, even those that induce immunodominant 
responses, may not be presented by Mtb-infected cells (166). A strategy to 
enumerate T cell recognition of Mtb infection could broaden our understanding of 
host−pathogen interactions and assist in the development of new vaccines. 
Vaccination with immunodominant antigens such as Ag85b and ESAT6 
induces CD4 T cell responses that provide limited protection (233, 234); thus 
perhaps these antigens are not the best stimulators of protective immunity. In 
addition, the recruitment of memory T cell responses specific for the vaccinated 
immunodominant antigens is only transiently augmented (160, 235). Our findings 
identify a population of polyclonal CD8 T cells that recognize Mtb-infected 
macrophages, supporting a previous study that showed cytotoxic functions of 
polyclonal CD8 T cells from infected mice in killed Mtb-infected cells (223). For 
efficient vaccine development, it may be useful to screen for (and eliminate from 
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consideration) Mtb antigens that resemble TB10.4, in that they induce robust T cell 
responses but fail to recognize and kill infected macrophages. Thus, future vaccine 
developments can benefit by identifying antigen targets based on their ability of 
being presented by infected cells rather than on their immunogenicity alone.  
The finding that a large proportion of CD8 T cells are specific for TB10.44-
11, yet the epitope is not able to be efficiently recognized on infected macrophages, 
is perplexing. Previous studies have identified that dendritic cells can pick up 
apoptotic vesicles containing live Mtb or parts of bacteria and prime naïve T cells 
in the LN (133, 134). While they portrayed this process in the context of T cell 
priming in the draining LN, this process could occur in the infected lung, where an 
uninfected bystander macrophage engulfs a dying Mtb-infected macrophage. 
Subsequently, peptides generated from dead bacteria or its proteins could be 
presented by uninfected APC (122). In parallel, if live Mtb actively inhibits antigen 
presentation (236), this could lead to MHC-restricted and TCR-dependent 
recognition biases towards uninfected cells rather than infected cells. Together, 
the persistence of the T cell response to uninfected cells would lead to 
inflammation unaccompanied by bacterial clearance. It is generally held that T cell-
dependent lung inflammation creates the necessary environment to promote a 
cough and person-to-person transmission. Thus, in agreement with the rationale 
by Comas et al. (110), hyperconserved T cell epitopes in the Mtb genome could 
drive T cell-mediated inflammation. In addition, our insights suggest that if the 
inflammation is mediated by immunodominant CD8 responses, inflammation may 
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occur in the absence of negative consequences to the bacterium as the T cell 
responses are unable to recognize infected cells.   
We propose that the epitopes presented by dendritic cells in LN, which 
prime T cell responses, were mismatched from those presented by macrophages 
in the lung at the site of infection during the effector function phase. We speculate 
that TB10.4, which is a secreted protein, may be taken up and presented by 
uninfected dendritic cells to prime T cell responses, but infected cells themselves 
do not present TB10.4 epitopes. The actual mechanisms of naïve T cell priming 
and recognition of bacteria-infected cells are important to facilitate development of 
strategies to enhance recognition of infected cells—either through blocking the 
antigen presentation by uninfected cells in the lung or by augmentation of antigen 
presentation by infected cells. One could employ immunopeptidomic analysis 
similar to the recent study that identified epitopes presented on BCG-infected 
macrophages (232). However, the main limitation of the study was the low rate of 
infection, with only 30% of cells being infected. The proportion of infected cells is 
crucial because it is unknown whether epitopes were presented on Mtb-infected 
DCs, or by uninfected DCs that acquire antigen through uptake of apoptotic blebs 
containing Mtb proteins (133, 134), or by the transfer of antigens from cell to cell 
(45). Sorting for infected and uninfected cells prior to analysis would increase the 
information regarding which antigens were presented by each subset, but the high 
number of cells needed for such an analysis (over 5x107 cells) may impede the 
sorting attempt. The immunopeptidomic study may help facilitate development of 
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a vaccine by considering which epitopes should be included in vaccine candidates 
to target infected cells, in order to overcome the decoy immune evasion. 
Last, but not least, there has been a growing body of literature supporting 
the role of antibodies against Mtb infections. Despite the correlation of higher 
antibody titers with disease severity (237) and inconsistent protections from 
antibody transfer (238, 239), mice without B cells or without ability to secrete 
antibodies are more susceptible to infection (240, 241). Depletion of B cells in non-
human primates also increased bacterial burden and lesions (242). Furthermore, 
elevated antibody titers have been identified in “resister” populations, emphasizing 
the evidence for a possible role for antibodies in Mtb protective immunity. 
Therefore, induction of antibody responses in addition to protective T cell 
responses could lead to the ultimate effective vaccine against tuberculosis. 
Finally, I have demonstrated that a single nucleotide polymorphism in the 
genome of Mtb can lead to the generation of a vastly different immunodominant 
CD8 T cell hierarchy. Therefore, the large genetic heterogeneity of existing clinical 
Mtb isolates in TB patients would be expected to drive diverse T cell responses. In 
addition, this dissertation showed that the majority of CD8 T cells induced in natural 
Mtb infections are inefficiently responsive to Mtb-infected cells. This may occur 
because the immunodominant CD8 T cells only “see” uninfected cells as targets 
and not the actual infected cells. In fact, the low overall frequency of T cells that 
recognize infected cells is consistent with Mtb using multiple strategies to evade 
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detection by the immune system. Characterizing the CD4 and CD8 T cells that can 
recognize low-MOI-infected macrophages, to mimic the physiological conditions of 
infected cells in the lungs (213), is crucial as this may identify antigens that are 
more likely to be presented during natural infection or post-vaccine challenge.  
To conclude, there are knowledge gaps in the current understanding of Mtb 
pathogenesis, its immune evasion strategies, and the immune responses 
generated. Given the long-standing interaction between Mtb and human 
populations, it is not surprising that immune pressures have shaped the evolution 
of Mtb as an invasive pathogen. The inability of host immunity to eliminate Mtb 
could be a consequence of the exploitation of host immunity by Mtb to aid in its 
transmission and avoid elimination. This dissertation presents a detailed example 
of an ongoing immune evasion strategy used by Mtb to diminish the contribution 
of CD8 T cells to host defenses. This work provides a foundation to understand 
and direct future studies to identify and generate protective CD8 T cell responses.    
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CHAPTER VII. MATERIALS AND METHODS 
Ethics Statement 
Studies involving animals were conducted following relevant guidelines and 
regulations, and the studies were approved by the Institutional Animal Care and 
Use Committee at the University of Massachusetts Medical School (Animal 
Welfare A3306-01), using the recommendations from the Guide for the Care and 
Use of Laboratory Animals of the National Institutes of Health and the Office of 
Laboratory Animal Welfare.  
Animal  
C57BL/6J, BALB/c and CB6F1 mice were purchased from Jackson Laboratories 
(Bar Harbor, ME) and housed under specific pathogen-free conditions at University 
of Massachusetts Medical School (UMMS) animal facilities. Mice were 8 to 9 
weeks old at the start of all experiments. C57BL/6J, BALB/c and CB6F1 mice were 
used for in vivo infection and as donor for isolating thioglycolate-elicited peritoneal 
macrophages. Infected mice were housed in biosafety level 3 facilities under 
specific pathogen-free conditions at UMMS.  
Thioglycolate-elicited peritoneal macrophages (TGPM) 
Thioglycolate-elicited peritoneal macrophages were obtained 4-5 days after 
intraperitoneal injection of donor mice with 3% thioglycolate solution, as described 
(34). CD11b microbeads (Miltenyi, Biotec, Germany) were used to purify for 
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macrophages population. 1x105 or 1x106 macrophages were plated per well of 96-
well plate or Nunc Up-Cell 12-well plate. Macrophages were maintained in culture 
with RPMI 1640 media (Invitrogen Life Technologies, ThermoFisher, Waltham, 
MA) supplemented with 10 mM HEPES, 1 mM sodium pyruvate, 2 mM L-glutamine 
(all from Invitrogen Life Technologies) and 10% heat-inactivated fetal bovine 
serum (HyClone, GE Healthcare Life Sciences, Pittsburgh, PA), referred as 
supplemented complete media.  
Generation of TCR retrogenic mice 
TCR retroviral constructs and retrogenic mice were generated using protocols 
developed by the Vignali lab as described (243, 244). Details of the TCRs and 
cloning strategies were discussed in (161, 166). Retroviral-mediated stem cell 
gene transfer was performed using congenic marked bone marrow and transferred 
into opposite-marked recipients that were lethally-irradiated at 1200 rads 
administered using a GammaCell 40 Cs137 Irradiator (Theratronics, Ottawa, ON, 
Canada). Reconstitution was measured 6-8 weeks later.  
Generation of CD8 and CD4 T cell lines 
Retrogenic mice expressing TB10RgL, TB10RgR, TB10RgP and TB10Rg3 TCR 
specific for the TB10.44-11 epitope were generated as previously described (161, 
166). In short, CD8 T cells were isolated from these mice by negative isolation with 
MojoSort (Biolegend), stimulated in vitro with irradiated splenocytes pulsed with 
the peptide TB10.44-11 in complete media containing IL-2. After the initial 
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stimulation, these T cells were split every two days for 3-4 divisions and rested for 
two to three weeks. After the initial stimulation, the cells were cultured in complete 
media containing IL-2 and IL-7.  
Peptides 
Polymorphic peptides A10T, A10V, P9S, and M11I were purchased from Genscript 
(Piscataway, NJ). WT (IMYNYPAM), negative control (IMANAPAM), Mtb32a309-318 
(GAPINSATAM) and ESAT61-15 (MTEQQWNFAGIEAAA) peptides were 
purchased from New England Peptides (Gardner, MA). TB10.4 peptide library was 
obtained from BEI Resource. 
Trivax vaccination and generation of antigen-specific CD8 T cells. 
 “Amphi-TB1020-28” (MFVMFVQGYAGTLQSL) and Mtb32a309-318 (GAPINSATAM) 
peptides were purchased from Genscript (Piscataway, NJ) and reconstituted in 
DMSO. High molecular weight polyinosinic:polycytidylic acid [poly(I:C)] was 
obtained from InvivoGen (San Diego, CA). Anti-CD40 mAb (clone FGK4.5) was 
purchased from BioXCell (West Lebanon, NH). Trivax vaccines were prepared by 
mixing 100 μM of peptide, 50 μg poly(I:C), and 50 μg aCD40 mAb, in a total volume 
of 200 μL sterile PBS and administered intravenously. Mice were boosted with the 
same vaccine 3 weeks later. CD8 T cells were isolated from spleen by negative 





Mycobacterium tuberculosis stains 
Unless indicated, Erdman strain was use for in vivo infection, and H37Rv strain 
was used for in vitro infection. ErdWT and ErdA10T were generated from Erdman 
background (as described below and in Chapter IV) and used for both in vivo and 
in vitro infections. DesxH strain was gifted from Dr. Jennifer Philips (Washington 
University at St. Louis) and used for in vitro infection. Barcoded clinical isolate pool 
was gifted from Dr. Sarah Fortune (Harvard University), and used in competitive 
infection. 
In vitro infection 
 Indicated Mtb of each experiment was thawed, grown in 7H9 media until 
reaching log-phase with OD600 of 0.6-1, washed, and opsonized with TB coat 
(RPMI 1640, 1% heat-inactivated FBS, 2% human serum, 0.05% Tween-80) 
before filtering through 5uM filter to remove clumps. The bacteria were counted in 
Petroff-Hausser chamber before adjusting the volume to respective multiplicity of 
infection (MOI) of interest. Actual MOI were determined by lysing bacterial culture 
with 10% Triton X-100 in water, serial diluting the lysates and plating in on 
Middlebrook 7H10 or 7H11 plates. Colony forming unit (CFU) was enumerated 





Mtb-Infected Macrophage ELISpot (MIM-E) and Intracellular Cytokine 
Staining (MIM-ICS) 
MIM-E and MIM-ICS were previously described (169). Briefly, TGPMs were 
isolated and infected in vitro at indicated MOI overnight. Infected and uninfected 
TGPMs were harvested the next day and plated 1x105 cells per well on ELISpot 
plate that had been coated with the IFNg capture antibody and blocked with 
complete media as per the manufacturer protocol, or on 96-well plates. Where 
indicated, 10μM single peptides or 2 μg/ml peptide megapool 300 were added to 
uninfected macrophage prior to the addition of T cells. Indicated T cells were 
isolated and co-incubated with TGPMs at 37C in non-shaking 5% CO2 incubator 
18-24 hours and follow manufacturer protocol for ELISpot development (BD 
Bioscience), or 5 hours and follow with standard ICS staining. 
RMA-S assay 
RMA-S H-2Kb cell line was gifted from Dr. Lawrence Stern laboratory (University 
of Massachusetts Medical School, Worcester MA) and maintained in completed 
RPMI. RMA-S cells were plated 5x104 per well in 96-well plates. WT and 
polymorphic peptides were titrated starting at 100uM down to 1pM and incubated 
onto RMA-S cells overnight at 27C in 5% CO2 incubator. RMA-S cells were 
subsequently shifted to 37C in 5%CO2 incubator for 1-2 hours before washing and 




Measurement of cell proliferation.  
Analysis TB10Rg3 cell proliferation was measured in vitro after stimulation by 
labeling purified T cells with 5 μM of the cell proliferation dye eFluor 450 
(eBiosciences). Proliferation, as measured by dye dilution, was measured by flow 
cytometry 72 hours after co-culture with APCs coated with a serial dilution of 
peptides 
Mouse infections 
Eight- to nine-week old female C57BL/6, BALB/c, or CB6F1 mice were infected via 
the aerosol route with indicated bacterial strains in each experiment. Frozen 
bacterial stocks were thawed, diluted in 0.9% NaCl - 0.02% Tween 80), and 
sonicated before loading into a nebulizer for Glas-col aerosol chamber (Terre 
Haute, IN) to deliver approximately 100 CFU of bacteria to the lungs of each 
mouse. The Mtb infecting dose from the lung were evaluated 24 hour after aerosol 
infection by plating lung homogenates on 7H11 agar plates from Hardy Diagnosis. 
Animal experimentation was performed under authorization from IACUC. At 
different times post-infection, mice were euthanized, lungs were removed after 
perfusion of pulmonary arteries with 10mL of cold RPMI1640. Lung cell 
suspensions were prepared by coarse dissociation using the GentleMACS tissue 
dissociator (Miltenyi Biotec, Germany). Tissue was digested for 30 min at 37°C 
with 250 U/mL collagenase (Sigma) in complete RPMI1640 followed by 
homogenization in the GentleMACS dissociator and sequential straining through 
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70 μm and 40 μm nylon cell strainers (Falcon). Lungs and spleens were also 
aseptically removed, individually homogenized, and plated to determine viable 
bacteria. 
Peptide library screening 
At indicated timepoint post infection, mice were euthanized by CO2 inhalation and 
cervical dislocation. Lungs and spleens were harvested and processed as describe 
above. Total lung cells were enumerated and 1x105 cells were plated in 96-well 
plates. Each peptide in peptide library and control peptides were diluted and added 
to the plate in triplicates. The cells were incubated at 37C 5%CO2 for 48 hours 
before supernatants were filtered through 0.2uM plate filter and subsequently 
determined the amount of secreted IFNg by ELISA (Biolegend, CA)  
Flow cytometry 
The following cell surface antigens were detected by flow cytometry using Zombie 
Violet or Aqua Fixable viability dye and the following antibodies: mouse CD4 (clone 
GK1.5), CD8 (clone 53-6.7), CD3ε (clone 145-2C11), CD19 (clone 6D5), CD44 
(clone IM7), CD62L (clone MEL-14), CD127 (clone A7R34), KLRG1 (clone 
2F1/KLRG1), CD69 (clone H1.2F3), IFNg (clone XMG1.2), F4/80 (clone BM8) and 
H-2Kb (clone AF6-88.5) (all from Biolegend). BV421-conjugated TB10.44-11-
loaded, BV421-conjugated IMYNYPTM-loaded, PE-conjugated Mtb32a309-318-
loaded H-2Kb tetramers, APC-conjugated ESAT6-loaded I-Ab tetramer, PE-
conjugated TB10.420-28-loaded H-2Kd tetramer and BV421-conjugated TB10.473-88-
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loaded I-Ad tetramer were obtained from the National Institutes of Health Tetramer 
Core Facility (Emory University Vaccine Center, Atlanta, GA). (Samples were fixed 
with 1% paraformaldehyde/PBS for 1 hour before being analyzed by a 
MACSQuant flow cytometer (Miltenyi Biotec). FlowJo Software (Tree Star, 
Portland, OR) was used to analyze the collected data. Single lymphocytes were 
gated by forward scatter versus height and side scatter for size and granularity, 
and dead cells were excluded. 
Lung cell purification 
Following infections, mice were euthanized, lungs were aseptically removed, 
individually homogenized for cell isolation. Pulmonary cells were purified by 
positive selection using anti-CD90.2 microbeads on AutoMACS (Miltenyi Biotec, 
Germany). The isolated cells were counted on a hemocytometer and plated in 
supplemented complete RPMI 1640 media.  
Barcoded clinical isolate pool infection 
Barcoded Mtb strain generation, infection, and analysis were previously described 
(188). Briefly, selected clinical isolates were individually tagged with unique 8 
basepair sequence, grown to log phase, pooled, and used for intravenous infection 
at 1x106 Mtb per mouse. At indicated time post infection, lungs and spleens were 
harvested, homogenized and plated on 7H10 supplemented with oleic albumin 
dextrose catalase (OADC) and 20 ng/ml kanamycin. After 3 weeks of incubation, 
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the plates were counted for CFU, and colonies were scraped for genomic DNA 
extraction and sequencing by NextSeq and analysis using Python. 
Generation of isogenic ErdWT and ErdA10T by oligo recombineering 
Oligo recombineering with long oligo containing desired base pair change were 
generated as described previously (208, 209, 245). Shortly, Erdman was grown in 
7H9 broth into a log phase before following standard protocol to electroporate 
pKM444 plasmid containing RecT annealase. Electroporated strains was selected 
on 7H10 agar plates containing 20 ng/ml kanamycin, picked at 3 weeks post 
plated, and PCR verify the presence of pKM444 plasmid. An Erdman strain 
containing the Che9 phage RecT producing plasmid was grown in 7H9 broth to an 
O.D. of 0.5.  Anhydrotetracycline (Atc) was added to a final concentration of 500 
ng/ml to induce expression of RecT from the PTet promoter; the cells were grown 
overnight and prepared for electroporation with esxHA10T-conferring oligo (1 ug) 
and an oligo targeting the rpsL gene (0.1 ug) designed to generate a K43R 
mutation in the RpsL protein, which confers resistance to streptomycin. Following 
outgrowth, the culture was plated on 7H10 agar plates containing 20 ng/ml 
streptomycin.  Selection of streptomycin screens for cells that pick up the DNA and 
are recombinogenic, increasing the frequency of finding the desired SNP.  





RT-PCR of mycobacterial mRNAs 
To quantitate expression of Mtb genes, indicated bacteria were grown to OD600 
of 0.8-1 before centrifugation to pellet intact bacterial cells. Bacterial pellets were 
resuspending in TRIzol (Invitrogen) and quickly homogenizing with silica beads 
and Bead beater homogenizer. RNA was extracted using Direct-zol RNA Miniprep 
Plus Kits (Zymo Research, Irvine CA). RT-PCR was carried out as previously 
described (127) with mRNA copy number normalized to the constitutively 
expressed 16S rRNA. The following RT-PCR primers were used in this study.  
16S rRNA:  Fw 5’-AGCTCGTAGGTGGTTTGTCG-3’  
Rv 5’-CCACCGCTACACCAGGAATT-3’;  
Rv0288:  Fw 5’-AGCTTGGGTGCCGAGAT-3’  
Rv 5’-TGCTGGACATCGCATGATAG-3’;  
Rv0287:  Fw 5’-GCTCAGGCGTTTCACCA-3’  
Rv 5’-CCAACAAGGTGTTGACTTTGG-3’;  
Rv3875:  Fw 5’-GTCCATTCATTCCCTCCTTGAC-3’  
Rv 5’-TTGCTGGACACCCTGGTA-3’;  
Rv1886c:  Fw 5’-ACAACTCACCTGCGGTTTAT-3’  
Rv 5’-GACAGTCCCGACTGGTAGTA-3’;  
Rv0125:  Fw 5’-AAGAGACATTGAACGGGTTGAT-3’  
Rv 5’-CTGGGACAGCTGGAAGTTATC-3’;  
Rv3874:  Fw 5’-ATCTCCGGCGACCTGAA-3’  
Rv 5’-CGAGTTCCTGCTTCTGCTTAT-3’;  
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Data are represented as mean ± standard error of the mean (SEM). For comparing 
two groups, a two-tailed, unpaired student’s t-test was used. For more than two 
groups, the data were analyzed using a one-way ANOVA. A p value < 0.05 was 
considered to be statistically significant. Analysis was performed using GraphPad 





APPENDIX: THE INVESTIGATION OF GRANULYSIN-MEDIATED CD8 T CELL 
CYTOTOXICITY DURING TUBERCULOSIS 
 
Rujapak Sutiwisesak1 and Samuel Behar1 
 
1Department of Microbiology and Physiological Systems, University of 







R.S. and S.B designed all experiments. R.S. performed all experiments and 








CD8 T cells, also known as cytotoxic T lymphocytes (CTL), recognize and 
eliminate infected cells by their effector molecules, which fall into two broad 
categories: cytotoxins, which are stored in specialized cytolytic granules, and 
cytokines such as IFNg and other related membrane-associated proteins, which 
are synthesized de novo (246). CD8 T cells also mediate killing through the Fas-
Fas ligand (FasL) pathway, which is upregulated upon target cell stimulation and 
inducec downstream caspase ultimately leading to apoptosis of the target cell. 
Although CTL have been shown to use IFNg-, FasL- and cytotoxic-mediated killing 
during tuberculosis in murine model (82, 83, 86, 90, 91, 223), the contribution of 
cytolysis by human cytolytic granules are not well-understood.  
Murine cytolytic granules contain granzymes (Gzm) and perforin (PFN). 
Perforin is a pore-forming molecule that is necessary for the delivery of granzymes, 
which induces apoptosis. Perforin and granzymes are released early after CD8 T 
cell activation into the immunological synapse between the CD8 T cell and a target 
cell (247). The process of cytotoxic degranulation is class I MHC-restricted and 
proposed to play an important role in control of in vivo Mtb infection (83, 223). 
However, these components are unable to kill intracellular bacteria. A major 
cytotoxic granule present in human and non-human primates, but not in mice, is a 
saponin-like pore forming protein called granulysin (GNLY) (248). Granulysin 
alters the membrane integrity on bacteria and mediates the antimicrobial activity 
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of CTL against Mtb in human, which leads to the direct killing of intracellular 
mycobacteria in vitro (85). 
 
Figure A.1: Granulysin is hypothesized to enhance CD8 T cell cytotoxic functions 
and provide better protection against Mtb infection 
 
Since murine model lacks granulysin in cytotoxic granule components, in 
vivo studies to elucidate the roles of granulysin during Mtb infection had not been 
feasible. After the generation of granulysin-transgenic (GNLY-Tg) mice (249), 
GNLY-Tg mice have been shown to be protected and survive from intracellular 
Toxoplasma gondii and Trypanosoma cruzi infections while they are lethal to WT 
mice (250). Given that human CD8 T cells recognize Mtb infected macrophages 
and directly kill through granulysin in vitro, in this appendix of dissertation, I explore 
the roles of granulysin during Mycobacteria tuberculosis (Mtb) infection in vivo. We 
hypothesize that granulysin enhances the cytotoxic functionalities of CD8 T cells 




GNLY is expressed in human CD8 T cells 
To set up the system of granulysin detection, I tested the conditions to 
stimulate GNLY expressions and detection with the human GNLY antibody for 
intracellular staining. Consistent with literature, IL-2 (not shown) and IL-15 are the 
strongest stimulators for the expression of GNLY in human PBMCs (Figure A.2). 
 
Figure A.2: GNLY is expressed in human CD8 T cells 
Human PBMCs were isolated from peripheral blood and stimulated in vitro with 
anti-human CD3 and anti-human CD28 antibodies, with or without recombinant IL-
15 cytokines. At 8 days post stimulations, cells were stained for granulysin and 




GNLY is expressed in NK cells, but not CD8 T cells, of GNLY-Tg mice 
We subsequently sought to verify the granulysin expressions of GNLY-Tg 
mice using exact protocol from the research group who generated the transgenic 
mice (249). Even though we were able to detect the GNLY expression only in NK 
cells, to our surprise, GNLY was not detectable in CD8 T cells in any stimulation 
conditions (Figure A.3). 
 
Figure A.3: GNLY is expressed in GNLY-Tg NK cells, but not CD8 T cells 
Spleens from C57BL/6 littermate control and GNLY-Tg mice were isolated and 
stimulated in vitro with anti-CD3 and anti-CD28 antibodies, with indicated 
cytokines. At 12 days post stimulations, cells were stained for granulysin and 
granzyme expression. Cells were gated by NK1.1 and CD8 antibodies, followed 
by isotype controls from GzmB and GNLY.  
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Generation of antigen-specific GNLY-Tg CD8 T cell line 
 We considered the possibility that granulysin expression needs high 
amount of stimulation to be expressed, and short-term stimulation might not 
suffice. We therefore vaccinate GNLY-Tg and C57BL/6 littermate control mice with 
Trivax-B8R vaccine to generate B8R-specific CD8 T cells lines (Figure A.4A). We 
elected for B8R epitope because B8R has been shown to be a strong stimulator 
during vaccination (160) and H-2Kb/B8R tetramer is available to use for detection. 
At 2 weeks post boost, we isolated splenocytes and stimulated in vitro with IL-2 or 
IL-15. However, we could not detect granulysin expression on CD8 T cells at 5 
days post stimulations (Figure A.4B). We therefore derived CD8 T cells from 
Trivax-B8R vaccinated GNLY-Tg and C57BL/6 littermate control into primary B8R-
specific CD8 T cell lines. At 3 weeks post stimulation and derivation, CD8 T cell 
lines from both GNLY-Tg and C57BL/6 littermate control continuously expressed 











Figure A.4: Generation of GNLY-Tg antigen-specific CD8 T cell lines 
(A) C57BL/6 littermate control and GNLY-Tg mice were vaccinated with TrivaxB8R 
(anti-CD40, Poly(I:C) and B8R peptide) and boosted 3 weeks afterward. (B) 
Spleens were isolated at 2 weeks post vaccination and stimulated in vitro with 
indicated cytokines. At 5 days post stimulations, cells were stained for granulysin 
and granzyme expression. Cells were gated by NK1.1 and CD8 antibodies, 
followed by isotype controls from GzmB and GNLY. (C) Spleens were isolated, 
and CD8 T cells were purified with untouched negative selection kit. Purified CD8 
T cells were subsequently stimulated in vitro with B8R-pulsed irradiated 
splenocytes with IL-2 supplement. At 3 weeks post stimulations, cells were stained 
for granulysin and granzyme expression. Cells were gated on CD8, followed by 





GNLY-Tg CD8 T cells can produce granulysin under limited stimulation 
conditions 
 To further determine whether there are conditions that GNLY would express 
in CD8 T cells, we subsequently restimulated B8R CD8 T cell line with B8R-pulsed 
splenocytes supplementing with various combinations of IL-2, IL-7, IL-12, IL-15, 
and IL-21 cytokines. For the first time, we were able to induce and detect 
granulysin production by CD8 T cells from GNLY-Tg mice at day 8 post stimulation 
(Figure A.5). Similar to human CD8 T cells, IL-2 and IL-15 were the strongest 
stimulators for GNLY production. Importantly, subsequent stimulations of the cell 
line appeared to lower the threshold for GNLY production, allowing granulysin to 




Figure A.5: GNLY-Tg CD8 T cells can produce granulysin under limited 
stimulation conditions 
B8R-specific C57BL/6 littermate control and GNLY-Tg CD8 T cell lines were 
stimulated in vitro with B8R-pulsed irradiated splenocytes and indicated cytokines. 
At indicated days post stimulations, cells were stained for granulysin and granzyme 




Granulysin-transgenic mice do not exhibit better control of Mycobacterium 
tuberculosis infection 
 Given that granulysin can be expressed on CD8 T cells, but heavy 
stimulations were needed, we decided to infect C57BL/6 littermate control and 
GNLY-Tg mice and determined the contribution of granulysin at the chronic phase 
of infection. At 16 weeks post infection, despite ability to detect granulysin in NK 
cells in pulmonary compartment, both antigen-specific and non-specific CD8 T 
cells did not produce granulysin (Figure A.6A). There were no differences in the 
total numbers of NK cells, antigen-specific and non-specific CD8 T cells, and the 
MPEC and SLEC phenotypes of CD8 T cells were not different between GNLY-Tg 
mice and littermate controls (Figure A.6B-E). Interestingly, more than half of 
granzymeB-expressing NK cells were expressing granulysin (Figure A.6F). Finally, 
there was no differences in pulmonary bacterial burdens. Together, this data 
shows that granulysin-expressing NK cells do not provide protection during Mtb 
infection. However, the role of granulysin on CD8 T cells remains unknown as the 










Figure A.6: GNLY-Tg mice do not exhibit better control of Mtb infection 
Age-matched C57BL/6 littermate control and GNLY-Tg mice were infected with 
Erdman Mtb at ~100 CFU. At 16 weeks post infected, infected mice were sacrificed 
for flow cytometry and bacterial control analysis. (A) Representative flow cytometry 
plots of granulysin and granzyme staining on indicated tetramer positive and 
tetramer negative CD8 T cells or NK cells. Cells were gated by isotype controls 
from GzmB and GNLY. (B) Proportion of CD8 T cells and NK cells in the lung of 
infected mice. (C) Proportion of tetramer positive cells in pulmonary CD8 T cells of 
infected mice. (D) Frequencies of activated CD8 T cell, granzyme B -expressing 
CD8 T cell, short-lived effector CD8 T cells, and memory precursor CD8 T cells in 
the lung of infected mice. (E) Total numbers of pulmonary CD8 T cells, antigen-
specific CD8 T cells, and NK cells. (F) Proportion of NK cells that express both 
GzmB and GNLY or only GzmB. (G) Pulmonary bacterial loads of C57BL/6 
littermate control and GNLY-Tg mice. Statistical testing by a two-tailed, unpaired 




Adoptive transfer of CD8 T cells from GNLY-Tg mice do not exhibit better 
control of Mtb infection 
 We considered the observation that transgenic CD8 T cells needed to be 
heavily stimulated to express granulysin. To remove the other crucial 
immunological players during tuberculosis and focus CD8 T cells to be the sole 
player, I adoptively transferred purified naïve CD8 T cells from GNLY-Tg or 
C57BL/6 littermate control to TCRa KO recipients that lacks T cells. The adoptive 
transfer animals were infected via aerosol route with Mtb at ~100 CFU one day 
after. Despite successful transferring of CD8 T cells which yielded the same 
numbers and similar phenotypes of CD8 T cells in the lungs and spleens of infected 
mice (Figure A.7A-B), we were not able to detect any granulysin productions from 
CD8 T cells (data not shown). Although CD8 T cells from both GNLY-Tg and 
C57BL/6 mice helped lower the number of bacteria significantly compared to the 
non-transferred animals, there was no differences in pulmonary and splenic 
bacterial burdens between the groups (Figure A.7C-D). In addition, we did not 
observe a prolong survival when extending the study further (Figure A.7E). 
Together, we did not detect granulysin nor its contribution on CD8 T cells to 






Figure A.7: Adoptive transfer of CD8 T cells from GNLY-Tg mice do not 
exhibit better control of Mtb infection 
Age-matched C57BL/6 littermate control and GNLY-Tg mice were used as donors 
to purify CD8 T cells for adoptively transferring to TCRa KO recipients 24 hours 
prior to aerosol infection. At 5 weeks post infected, infected mice were sacrificed 
for flow cytometry and bacterial control analysis. (A) Total numbers of pulmonary 
and splenic CD8 T cells following infection. (B) Frequencies of memory precursor 
CD8 T cells, short-lived effector CD8 T cells, and activated CD8 T cell in the lung 
of infected mice. (C-D) Bacterial burden in the (C) lungs and (D) spleens of TCRa 
KO adoptively transferred with CD8 T cells from C57BL/6 littermate control or 
GNLY-Tg mice. (E) Survival study of Mtb-infected adoptively transferred TCRa KO 
mice. Statistical testing was by one-way ANOVA, using the Dunnett posttest 






Consistent with previous reports, IL-2 and IL-15 were the strongest 
stimulators for the expression of GNLY in human PBMCs (251), mouse CD8 T 
cells and mouse NK cells (249). However, while GNLY expression in NK cells were 
detected following in vivo Mtb infection, no expression was detected in CD8 T cells. 
In addition, there was no difference in bacteria control between transgenic and wilt-
type mice. Our lab has previously identified the low amount of IL-2 detected in vivo 
following Mtb infection (Miye Jacques, unpublished observation).  This could partly 
contribute to the situation where there were not enough cytokines to stimulate 
GNLY expression on the GNLY-Tg CD8 T cells in vivo. In fact, poor production of 
IL-2 following Mtb infection potentially impairs immunity to TB. In particular, this 
could result in suboptimal activation of CD8 T cells. One could address this issue 
by giving the GNLY-tg or control mice with exogenous IL-2 and IL-15, and 
determining whether their ability to control bacterial growth in vitro is enhanced.  
However, based on our observations, we postulated that the GNLY-Tg mice 
did not have the appropriate expression on CD8 T cells similarly to human CD8 T 
cells as we expected. Despite the effort to use specific and strong promoter, the 
granulysin transgenic mice were generated using bacteria artificial chromosome 
system where the transgene was randomly integrated (249). The researchers 
performed in situ hybridization to identify the location of the transgene, and 
subsequently showed the RNA and protein expressions of granulysin. Yet, 
subsequent studies utilizing the GNLY-Tg mice did not display the detection of 
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GNLY protein on CD8 T cells (250). The incorrect GNLY expression, therefore, 
impeded our effort to study multiple aspects of granulysin including (1) granulysin 
contribution to resistance against in vivo Mtb infection and (2) whether the 
resistance was mediated by CD8 T cells.  
Given that granulysin has shown its cytotoxicity in vitro with human CD8 T 
cells (85), studying granulysin during in vivo Mtb infection would enhance the 
understanding of granulysin role for bacterial clearance. In human, granulysin 
consists of three different isoforms without known distinct functions (252). We have 
recently cloned human granulysin isoform 2 and 3 into retroviral vectors and 
expressed into stable cell lines, along with generating granulysin isoform 1 
lentiviral vector. We aim to transduce the granulysin-expressing virus into CD8 T 
cells for in vitro Mtb infection study, and generate retrogenic mice expressing 
granulysin to further elucidate the role of granulysin in vivo. 
This work will recognize T cell effector functions that are crucial for the 
control of Mtb infection and the potential targeted mechanisms to improve the 
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